<?xml version="1.0" encoding="UTF-8"?>
<OAI-PMH xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.openarchives.org/OAI/2.0/ http://www.openarchives.org/OAI/2.0/OAI-PMH.xsd">
  <responseDate>2024-05-03T02:27:39Z</responseDate>
  <request verb="GetRecord" identifier="oai:pubmedcentral.nih.gov:10110272" metadataPrefix="pmc">https:/www.ncbi.nlm.nih.gov/pmc/oai/oai.cgi</request>
  <GetRecord>
    <record>
      <header>
        <identifier>oai:pubmedcentral.nih.gov:10110272</identifier>
        <datestamp>2023-04-18</datestamp>
        <setSpec>cid</setSpec>
        <setSpec>pmc-open</setSpec>
      </header>
      <metadata>
        <article xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:ali="http://www.niso.org/schemas/ali/1.0/" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xsi:schemaLocation="https://jats.nlm.nih.gov/ns/archiving/1.3/ https://jats.nlm.nih.gov/archiving/1.3/xsd/JATS-archivearticle1-3.xsd" dtd-version="1.3" xml:lang="en" article-type="research-article">
          <processing-meta base-tagset="archiving" mathml-version="3.0" table-model="xhtml" tagset-family="jats">
            <restricted-by>pmc</restricted-by>
          </processing-meta>
          <front>
            <journal-meta>
              <journal-id journal-id-type="nlm-ta">Clin Infect Dis</journal-id>
              <journal-id journal-id-type="iso-abbrev">Clin Infect Dis</journal-id>
              <journal-id journal-id-type="publisher-id">cid</journal-id>
              <journal-title-group>
                <journal-title>Clinical Infectious Diseases: An Official Publication of the Infectious Diseases Society of America</journal-title>
              </journal-title-group>
              <issn pub-type="ppub">1058-4838</issn>
              <issn pub-type="epub">1537-6591</issn>
              <publisher>
                <publisher-name>Oxford University Press</publisher-name>
                <publisher-loc>US</publisher-loc>
              </publisher>
            </journal-meta>
            <article-meta>
              <article-id pub-id-type="accession">PMC10110272</article-id>
              <article-id pub-id-type="pmcid">PMC10110272</article-id>
              <article-id pub-id-type="pmc-uid">10110272</article-id>
              <article-id pub-id-type="pmid">36504254</article-id>
              <article-id pub-id-type="pmid">36504254</article-id>
              <article-id pub-id-type="doi">10.1093/cid/ciac938</article-id>
              <article-id pub-id-type="publisher-id">ciac938</article-id>
              <article-categories>
                <subj-group subj-group-type="heading">
                  <subject>Major Article</subject>
                  <subj-group subj-group-type="category-toc-heading">
                    <subject>Original Article</subject>
                  </subj-group>
                </subj-group>
                <subj-group subj-group-type="category-taxonomy-collection">
                  <subject>AcademicSubjects/MED00290</subject>
                </subj-group>
                <subj-group subj-group-type="category-oup-series">
                  <subject>Editor's Choice</subject>
                </subj-group>
              </article-categories>
              <title-group>
                <article-title>Non-<italic toggle="yes">Lactobacillus</italic>-Dominant and Polymicrobial Vaginal Microbiomes Are More Common in Younger South African Women and Predictive of Increased Risk of Human Immunodeficiency Virus Acquisition</article-title>
              </title-group>
              <contrib-group>
                <contrib contrib-type="author">
                  <name>
                    <surname>Wang</surname>
                    <given-names>Yiran</given-names>
                  </name>
                  <aff><institution>Center for Global Health and Diseases, Case Western Reserve University School of Medicine</institution>, <addr-line>Cleveland, Ohio</addr-line>, <country country="US">USA</country></aff>
                  <xref rid="ciac938-FM1" ref-type="author-notes"/>
                </contrib>
                <contrib contrib-type="author">
                  <name>
                    <surname>Noël-Romas</surname>
                    <given-names>Laura</given-names>
                  </name>
                  <aff><institution>Center for Global Health and Diseases, Case Western Reserve University School of Medicine</institution>, <addr-line>Cleveland, Ohio</addr-line>, <country country="US">USA</country></aff>
                  <aff><institution>Department of Obstetrics and Gynecology, University of Manitoba</institution>, <addr-line>Winnipeg</addr-line>, <country country="CA">Canada</country></aff>
                  <xref rid="ciac938-FM1" ref-type="author-notes"/>
                </contrib>
                <contrib contrib-type="author">
                  <name>
                    <surname>Perner</surname>
                    <given-names>Michelle</given-names>
                  </name>
                  <aff><institution>Sexually Transmitted Infectious and Bloodborne Pathogens Section, JC Wilt Infectious Disease Research Center, Public Health Agency of Canada</institution>, <addr-line>Winnipeg</addr-line>, <country country="CA">Canada</country></aff>
                  <xref rid="ciac938-FM1" ref-type="author-notes"/>
                </contrib>
                <contrib contrib-type="author">
                  <name>
                    <surname>Knodel</surname>
                    <given-names>Samantha</given-names>
                  </name>
                  <aff><institution>Center for Global Health and Diseases, Case Western Reserve University School of Medicine</institution>, <addr-line>Cleveland, Ohio</addr-line>, <country country="US">USA</country></aff>
                  <aff><institution>Department of Obstetrics and Gynecology, University of Manitoba</institution>, <addr-line>Winnipeg</addr-line>, <country country="CA">Canada</country></aff>
                  <xref rid="ciac938-FM1" ref-type="author-notes"/>
                </contrib>
                <contrib contrib-type="author">
                  <name>
                    <surname>Molatlhegi</surname>
                    <given-names>Refilwe</given-names>
                  </name>
                  <aff><institution>Department of Medical Microbiology, University of KwaZulu-Natal</institution>, <addr-line>Durban</addr-line>, <country country="ZA">South Africa</country></aff>
                </contrib>
                <contrib contrib-type="author">
                  <name>
                    <surname>Hoger</surname>
                    <given-names>Sarah</given-names>
                  </name>
                  <aff><institution>Department of Medical Microbiology and Infectious Diseases, University of Manitoba</institution>, <addr-line>Winnipeg</addr-line>, <country country="CA">Canada</country></aff>
                </contrib>
                <contrib contrib-type="author">
                  <name>
                    <surname>Birse</surname>
                    <given-names>Kenzie</given-names>
                  </name>
                  <aff><institution>Center for Global Health and Diseases, Case Western Reserve University School of Medicine</institution>, <addr-line>Cleveland, Ohio</addr-line>, <country country="US">USA</country></aff>
                  <aff><institution>Department of Obstetrics and Gynecology, University of Manitoba</institution>, <addr-line>Winnipeg</addr-line>, <country country="CA">Canada</country></aff>
                </contrib>
                <contrib contrib-type="author">
                  <name>
                    <surname>Zuend</surname>
                    <given-names>Christina Farr</given-names>
                  </name>
                  <aff><institution>Center for Global Health and Diseases, Case Western Reserve University School of Medicine</institution>, <addr-line>Cleveland, Ohio</addr-line>, <country country="US">USA</country></aff>
                </contrib>
                <contrib contrib-type="author">
                  <name>
                    <surname>McKinnon</surname>
                    <given-names>Lyle R</given-names>
                  </name>
                  <aff><institution>Department of Medical Microbiology and Infectious Diseases, University of Manitoba</institution>, <addr-line>Winnipeg</addr-line>, <country country="CA">Canada</country></aff>
                </contrib>
                <contrib contrib-type="author" corresp="yes">
                  <name>
                    <surname>Burgener</surname>
                    <given-names>Adam D</given-names>
                  </name>
                  <aff><institution>Center for Global Health and Diseases, Case Western Reserve University School of Medicine</institution>, <addr-line>Cleveland, Ohio</addr-line>, <country country="US">USA</country></aff>
                  <aff><institution>Department of Obstetrics and Gynecology, University of Manitoba</institution>, <addr-line>Winnipeg</addr-line>, <country country="CA">Canada</country></aff>
                  <aff><institution>Unit of Infectious Diseases, Department of Medicine Solna, Center for Molecular, Medicine, Karolinska Institute, Karolinska University Hospital</institution>, <addr-line>Stockholm</addr-line>, <country country="SE">Sweden</country></aff>
                  <xref rid="ciac938-cor1" ref-type="corresp"/>
                  <xref rid="ciac938-FM2" ref-type="author-notes"/>
                  <!--adam.burgener@case.edu-->
                </contrib>
              </contrib-group>
              <author-notes>
                <fn id="ciac938-FM1">
                  <p>Y. W., L. N.-R., M. P., and S. K. contributed equally to this work.</p>
                </fn>
                <corresp id="ciac938-cor1">Correspondence: A. Burgener, Center for Global Health and Diseases, Case Western Reserve University, 2109 Adelbert Rd, Biomedical Research Bldg, Cleveland, OH 44106 (<email>adam.burgener@case.edu</email>).</corresp>
                <fn id="ciac938-FM2" fn-type="COI-statement">
                  <p><bold><italic toggle="yes">Potential conflicts of interest.</italic></bold> M. P. reports participation as an editorial advisory board member for Global Graduate and Postgraduate Research Publishing (unpaid, started October 2022); and a leadership role as a board member of the not-for-profit charity Bridging Villages Inc (unpaid). All other authors report no potential conflicts.</p>
                  <p>All authors have submitted the ICMJE Form for Disclosure of Potential Conflicts of Interest. Conflicts that the editors consider relevant to the content of the manuscript have been disclosed.</p>
                </fn>
              </author-notes>
              <pub-date pub-type="collection">
                <day>15</day>
                <month>4</month>
                <year>2023</year>
              </pub-date>
              <pub-date pub-type="epub" iso-8601-date="2022-12-12">
                <day>12</day>
                <month>12</month>
                <year>2022</year>
              </pub-date>
              <pub-date pub-type="pmc-release">
                <day>12</day>
                <month>12</month>
                <year>2022</year>
              </pub-date>
              <volume>76</volume>
              <issue>8</issue>
              <fpage>1372</fpage>
              <lpage>1381</lpage>
              <history>
                <date date-type="received">
                  <day>02</day>
                  <month>9</month>
                  <year>2022</year>
                </date>
                <date date-type="editorial-decision">
                  <day>04</day>
                  <month>12</month>
                  <year>2022</year>
                </date>
                <date date-type="corrected-typeset">
                  <day>06</day>
                  <month>1</month>
                  <year>2023</year>
                </date>
              </history>
              <permissions>
                <copyright-statement>© The Author(s) 2022. Published by Oxford University Press on behalf of Infectious Diseases Society of America.</copyright-statement>
                <copyright-year>2022</copyright-year>
                <license>
                  <ali:license_ref specific-use="textmining" content-type="ccbyncndlicense">https://creativecommons.org/licenses/by-nc-nd/4.0/</ali:license_ref>
                  <license-p>This is an Open Access article distributed under the terms of the Creative Commons Attribution-NonCommercial-NoDerivs licence (<ext-link ext-link-type="uri" xlink:href="https://creativecommons.org/licenses/by-nc-nd/4.0/">https://creativecommons.org/licenses/by-nc-nd/4.0/</ext-link>), which permits non-commercial reproduction and distribution of the work, in any medium, provided the original work is not altered or transformed in any way, and that the work is properly cited. For commercial re-use, please contact journals.permissions@oup.com</license-p>
                </license>
              </permissions>
              <self-uri xlink:href="ciac938.pdf"/>
              <abstract>
                <title>Abstract</title>
                <sec id="s1">
                  <title>Background</title>
                  <p>Adolescent girls and young women aged 15‒24 years in sub-Saharan Africa are at disproportionate risk of human immunodeficiency virus (HIV) infection. Given the known association between vaginal microbial dysbiosis and HIV susceptibility, we performed an age-stratified analysis of the vaginal microbiome in South African women and compared this to their risk of HIV acquisition.</p>
                </sec>
                <sec id="s2">
                  <title>Methods</title>
                  <p>Vaginal microbiome data were generated by mass spectrometry–based proteomic analysis of cervicovaginal lavages collected from participants (n = 688) in the Centre for the AIDS Programme of Research in South Africa (CAPRISA) 004 trial. Participants were grouped by age (18–19 years, n = 93; 20–24 years, n = 326; 25–41 years, n = 269).</p>
                </sec>
                <sec id="s3">
                  <title>Results</title>
                  <p>Four microbiome types were identified based on predominant taxa, including <italic toggle="yes">Lactobacillus crispatus</italic> (CST-LC, 12.2%), <italic toggle="yes">Lactobacillus iners</italic> (CST-LI, 43.6%), <italic toggle="yes">Gardnerella vaginalis</italic> (CST-GV, 26.6%), or polymicrobial (CST-PM, 15.1%). Women aged 18–19 and 20–24 years had increased CST-PM and a non-<italic toggle="yes">Lactobacillus</italic>-dominant microbiome compared to those 25–41 years (odds ratio [OR], 3.14 [95% confidence interval {CI}, 1.12–7.87], <italic toggle="yes">P</italic> = .017; OR, 2.81 [95% CI, 1.07–7.09], <italic toggle="yes">P</italic> = .038, respectively; and OR, 1.65 [95% CI, 1.02–2.65], <italic toggle="yes">P</italic> = .028; OR, 1.40 [95% CI, 1.01–1.95], <italic toggle="yes">P</italic> = .030, respectively). The HIV incidence rate of women with CST-PM microbiome was 7.19-fold higher compared to women with CST-LC (hazard ratio [HR], 7.19 [95% CI, 2.11–24.5], <italic toggle="yes">P</italic> = .00162), which was also consistent in women aged 20–24 years (HR, 4.90 [95% CI, 1.10–21.9], <italic toggle="yes">P</italic> = .0375).</p>
                </sec>
                <sec id="s4">
                  <title>Conclusions</title>
                  <p>Younger women were more likely to have a higher-risk polymicrobial microbiome suggesting that vaginal microbiota are contributing to increased HIV-1 susceptibility in this group.</p>
                </sec>
                <sec id="s5">
                  <title>Clinical Trials Registration</title>
                  <p>NCT00441298.</p>
                </sec>
              </abstract>
              <abstract abstract-type="teaser">
                <p>Young women are at disproportionate risk of HIV infection. In this study, polymicrobial vaginal microbiomes that predict increased risk of HIV acquisition are more common in younger women, which may be a contributing factor to health disparities in HIV.</p>
              </abstract>
              <kwd-group>
                <kwd>HIV transmission</kwd>
                <kwd>vaginal microbiome</kwd>
                <kwd>young women</kwd>
              </kwd-group>
              <funding-group>
                <award-group award-type="grant">
                  <funding-source>
                    <institution-wrap>
                      <institution>South African National Research Foundation</institution>
                    </institution-wrap>
                  </funding-source>
                </award-group>
              </funding-group>
              <counts>
                <page-count count="10"/>
              </counts>
            </article-meta>
          </front>
          <body>
            <p>In sub-Saharan Africa, adolescent girls and young women (AGYW) aged 15–24 years are twice as likely to have human immunodeficiency virus (HIV) than males of the same age [<xref rid="ciac938-B1" ref-type="bibr">1</xref>]. Compared to their male counterparts, they acquire HIV infection at least 5–7 years earlier [<xref rid="ciac938-B1" ref-type="bibr">1</xref>]. AGYW aged 15–19 years are especially vulnerable to becoming infected [<xref rid="ciac938-B2" ref-type="bibr">2</xref>, <xref rid="ciac938-B3" ref-type="bibr">3</xref>]. In high-burden areas within South Africa, new infections are alarmingly high in AGYW, including 7.8% in those 15–19 years and 8.6% in those 20–24 years of age based on a recent meta-analysis [<xref rid="ciac938-B4" ref-type="bibr">4</xref>]. Antiretroviral agents formulated as vaginal gels [<xref rid="ciac938-B5" ref-type="bibr">5</xref>], rings [<xref rid="ciac938-B6" ref-type="bibr">6</xref>, <xref rid="ciac938-B7" ref-type="bibr">7</xref>], and pills [<xref rid="ciac938-B8" ref-type="bibr">8–10</xref>] have shown lower efficacy in those with lower adherence, and lower adherence rates are common in younger age groups [<xref rid="ciac938-B6" ref-type="bibr">6</xref>, <xref rid="ciac938-B11" ref-type="bibr">11</xref>]. Recent trials of newer technologies such as long-acting injectables, including HIV Prevention Trials Network study 084, have shown high efficacy [<xref rid="ciac938-B12" ref-type="bibr">12</xref>] and provide further HIV prevention options for AGYW. Nevertheless, intensifying HIV prevention efforts, specifically in young women, could have significant public health impact, and lessons learned in studying young women would have relevance for epidemic regions like these in Africa and the global effort to stop HIV. Although social, high-risk behavior, access to or utilization of healthcare services, and economic factors may all contribute to increased susceptibility to HIV infection in young women, biological factors are also thought to play a significant role [<xref rid="ciac938-B13" ref-type="bibr">13</xref>].</p>
            <p>The mucosal surface of the female genital tract (FGT) is the major site of HIV infection in heterosexual transmission. Maturational changes in the FGT during adolescence include alterations to mucosal barrier function [<xref rid="ciac938-B14" ref-type="bibr">14</xref>], inflammatory processes, and microbiome composition [<xref rid="ciac938-B15" ref-type="bibr">15</xref>]. Low levels of certain <italic toggle="yes">Lactobacillus</italic> species (<italic toggle="yes">Lactobacillus crispatus</italic>) and increased levels of bacterial vaginosis–associated bacteria (BVAB) have been observed in some studies of AGYW, while others have found no differences in the vaginal microbiome between AGYW and adults [<xref rid="ciac938-B15" ref-type="bibr">15–17</xref>]. The microbiome has been shown to affect levels of proinflammatory cytokines, recruitment of HIV target cells, epithelial barrier function, innate immune function, and metabolite levels [<xref rid="ciac938-B18" ref-type="bibr">18–21</xref>]. An optimal vaginal microbiome is typically dominated by a single species of <italic toggle="yes">Lactobacillus</italic> in high abundance, which plays essential roles in the mucosal microenvironment, including producing lactic acid to lower the vaginal pH, supporting antipathogenic defense, and epithelial barrier integrity. While <italic toggle="yes">Lactobacillus</italic> microbiomes are protective against HIV [<xref rid="ciac938-B22" ref-type="bibr">22</xref>], diverse anaerobic bacterial communities associate with increased HIV susceptibility [<xref rid="ciac938-B23" ref-type="bibr">23</xref>]. This posits that the microbiome composition specific to young women may put them at greater risk of HIV.</p>
            <p>We have previously characterized the vaginal microbiome composition of women enrolled in the Centre for the AIDS Programme of Research in South Africa (CAPRISA) 004 trial [<xref rid="ciac938-B24" ref-type="bibr">24</xref>], which evaluated a vaginal microbicide containing tenofovir in protection from HIV in South African women. In this post hoc analysis, we analyzed the vaginal microbiome profiles in different age groups to examine the relationship among microbiome, age, and risk of HIV acquisition.</p>
            <sec sec-type="methods" id="ciac938-s0">
              <title>METHODS</title>
              <sec id="ciac938-s0.1">
                <title>Ethics</title>
                <p>Ethical approval of this study was provided by the University of Manitoba and University of KwaZulu-Natal human research ethics committees. Only women who provided written informed consent for storage of their specimens for future research were included in this study (NCT00441298).</p>
              </sec>
              <sec id="ciac938-s0.2">
                <title>Study Design</title>
                <p>This was a nested study in the CAPRISA 004 trial, the details of which are published elsewhere [<xref rid="ciac938-B5" ref-type="bibr">5</xref>]. Cervicovaginal lavage (CVL) samples were collected from study participants during concurrent pelvic examinations at quarterly visits. The last HIV-seronegative CVL sample from the closest time point prior to seroconversion was selected for analysis from the 61 women who went on to acquire HIV within the trial (cases), and all available women who remained uninfected (controls, n = 627), matched for time in the trial (N = 688). Sample time points analyzed for cases were taken at a mean time of 4.7 ± 3 months prior to HIV infection. For age-related analysis, women were grouped into 3 categories guided by epidemiological studies linking age to HIV infection risk: 18–19 years (n = 93), 20–24 years (n = 326), and 25–41 years (n = 269). Methods of statistical analysis and details on mass spectrometry for vaginal microbiome analysis are provided in the <xref rid="sup1" ref-type="supplementary-material">Supplementary Methods</xref>.</p>
              </sec>
            </sec>
            <sec sec-type="results" id="ciac938-s1">
              <title>RESULTS</title>
              <sec id="ciac938-s1.1">
                <title>Cohort Demographics</title>
                <p>We utilized previously published microbiome data from an HIV case-control study of the CAPRISA 004 vaginal microbicide trial [<xref rid="ciac938-B24" ref-type="bibr">24</xref>]. This included analysis of cervicovaginal samples from 701 HIV-negative women, which included samples from the last HIV-negative time point of the 63 women who went on to acquire HIV within the trial (cases) and the 638 women who remained uninfected (controls). Based on HIV risk findings associated with young women aged 15–19 and &lt;25 years [<xref rid="ciac938-B3" ref-type="bibr">3</xref>, <xref rid="ciac938-B25" ref-type="bibr">25</xref>], we first stratified 688 participants of the CAPRISA 004 trial by the following age groupings based on their age at study enrollment: 18–19 years (n = 93), 20–24 years (n = 326), and 25–41 years (n = 269). Many baseline clinical, behavioral, and demographic variables were comparable across age groups (<xref rid="ciac938-T1" ref-type="table">Table 1</xref>). However, women aged 18–19 years were more likely to live in rural areas, have a sexually transmitted infection (STI), and use depot medroxyprogesterone acetate (DMPA), and less likely to have herpes simplex virus type 2 (HSV-2), use vaginal insertion practices, and adhere to the tenofovir treatment regimen. Younger age was also associated with a lower proportion to have given birth, fewer lifetime sex partners, and a first sexual encounter at an earlier age.</p>
                <table-wrap position="float" id="ciac938-T1">
                  <label>Table 1.</label>
                  <caption>
                    <p>Clinical, Behavioral, and Demographic Characteristics of CAPRISA-004 Study Participants</p>
                  </caption>
                  <table frame="hsides" rules="groups">
                    <colgroup span="1">
                      <col valign="top" align="left" span="1"/>
                      <col valign="top" align="center" span="1"/>
                      <col valign="top" align="center" span="1"/>
                      <col valign="top" align="center" span="1"/>
                      <col valign="top" align="center" span="1"/>
                    </colgroup>
                    <thead>
                      <tr>
                        <th rowspan="2" align="left" colspan="1">Variable</th>
                        <th colspan="4" align="center" rowspan="1">Age Group</th>
                      </tr>
                      <tr>
                        <th align="center" rowspan="1" colspan="1">Overall</th>
                        <th align="center" rowspan="1" colspan="1">18–19 y</th>
                        <th align="center" rowspan="1" colspan="1">20–24 y</th>
                        <th align="center" rowspan="1" colspan="1">25–41 y</th>
                      </tr>
                    </thead>
                    <tbody>
                      <tr>
                        <td rowspan="1" colspan="1">Baseline demographics</td>
                        <td rowspan="1" colspan="1">688 (100)</td>
                        <td rowspan="1" colspan="1">93 (13.5)</td>
                        <td rowspan="1" colspan="1">326 (47.4)</td>
                        <td rowspan="1" colspan="1">269 (39.1)</td>
                      </tr>
                      <tr>
                        <td rowspan="1" colspan="1">ȃAge at visit, y, mean ± SD; range</td>
                        <td rowspan="1" colspan="1">24.4 ± 5.2; 18–41</td>
                        <td rowspan="1" colspan="1">18.7 ± 0.5; 18–19</td>
                        <td rowspan="1" colspan="1">21.7 ± 1.3; 20–24</td>
                        <td rowspan="1" colspan="1">29.7 ± 4.3; 25–41</td>
                      </tr>
                      <tr>
                        <td rowspan="1" colspan="1">ȃHIV seroconverters</td>
                        <td rowspan="1" colspan="1">61 (8.9)</td>
                        <td rowspan="1" colspan="1">8 (8.6)</td>
                        <td rowspan="1" colspan="1">35 (10.7)</td>
                        <td rowspan="1" colspan="1">18 (6.7)</td>
                      </tr>
                      <tr>
                        <td rowspan="1" colspan="1">ȃYears in trial, mean ± SD; range</td>
                        <td rowspan="1" colspan="1">1.6 ± 0.5; 0.2–2.4</td>
                        <td rowspan="1" colspan="1">1.5 ± 0.4; 0.2–2.3</td>
                        <td rowspan="1" colspan="1">1.6 ± 0.5; 0.3–2.4</td>
                        <td rowspan="1" colspan="1">1.6 ± 0.5; 0.3–2.4</td>
                      </tr>
                      <tr>
                        <td rowspan="1" colspan="1">ȃTFV arm</td>
                        <td rowspan="1" colspan="1">347 (50.4)</td>
                        <td rowspan="1" colspan="1">42 (45.2)</td>
                        <td rowspan="1" colspan="1">163 (50)</td>
                        <td rowspan="1" colspan="1">142 (52.8)</td>
                      </tr>
                      <tr>
                        <td rowspan="1" colspan="1">ȃRural</td>
                        <td rowspan="1" colspan="1">502 (73)</td>
                        <td rowspan="1" colspan="1">80 (86)</td>
                        <td rowspan="1" colspan="1">246 (75.5)</td>
                        <td rowspan="1" colspan="1">176 (65.4)</td>
                      </tr>
                      <tr>
                        <td rowspan="1" colspan="1">ȃGiven birth</td>
                        <td rowspan="1" colspan="1">547 (79.5)</td>
                        <td rowspan="1" colspan="1">61 (65.6)</td>
                        <td rowspan="1" colspan="1">241 (73.9)</td>
                        <td rowspan="1" colspan="1">245 (91.1)</td>
                      </tr>
                      <tr>
                        <td rowspan="1" colspan="1">ȃAge at sexual debut, y, mean ± SD; range</td>
                        <td rowspan="1" colspan="1">17.4 ± 2.1; 12–26</td>
                        <td rowspan="1" colspan="1">16.3 ± 1.4; 13–19</td>
                        <td rowspan="1" colspan="1">17.3 ± 1.7; 12–22</td>
                        <td rowspan="1" colspan="1">18 ± 2.4; 12–26</td>
                      </tr>
                      <tr>
                        <td rowspan="1" colspan="1">ȃTotal lifetime sex partners, mean ± SD; range</td>
                        <td rowspan="1" colspan="1">3.1 ± 9.4; 1–202</td>
                        <td rowspan="1" colspan="1">1.8 ± 1.2; 1–6</td>
                        <td rowspan="1" colspan="1">2.3 ± 2.2; 1–21</td>
                        <td rowspan="1" colspan="1">4.5 ± 14.8; 1–202</td>
                      </tr>
                      <tr>
                        <td rowspan="1" colspan="1">ȃAny STI reported in trial<sup><xref rid="ciac938-tblfn3" ref-type="table-fn">a</xref></sup></td>
                        <td rowspan="1" colspan="1">134 (19.5)</td>
                        <td rowspan="1" colspan="1">25 (26.9)</td>
                        <td rowspan="1" colspan="1">62 (19)</td>
                        <td rowspan="1" colspan="1">47 (17.5)</td>
                      </tr>
                      <tr>
                        <td rowspan="1" colspan="1">ȃHSV-2<sup><xref rid="ciac938-tblfn4" ref-type="table-fn">b</xref></sup></td>
                        <td rowspan="1" colspan="1"/>
                        <td rowspan="1" colspan="1"/>
                        <td rowspan="1" colspan="1"/>
                        <td rowspan="1" colspan="1"/>
                      </tr>
                      <tr>
                        <td rowspan="1" colspan="1">ȃȃHSV-2 seroprevalence at baseline</td>
                        <td rowspan="1" colspan="1">352 (51.2)</td>
                        <td rowspan="1" colspan="1">29 (31.2)</td>
                        <td rowspan="1" colspan="1">129 (39.6)</td>
                        <td rowspan="1" colspan="1">194 (72.1)</td>
                      </tr>
                      <tr>
                        <td rowspan="1" colspan="1">ȃȃHSV-2 seropositivity during trial</td>
                        <td rowspan="1" colspan="1">66 (9.6)</td>
                        <td rowspan="1" colspan="1">16 (17.2)</td>
                        <td rowspan="1" colspan="1">37 (11.3)</td>
                        <td rowspan="1" colspan="1">13 (4.8)</td>
                      </tr>
                      <tr>
                        <td rowspan="1" colspan="1">ȃRemained HSV-2 negative during trial</td>
                        <td rowspan="1" colspan="1">263 (38.2)</td>
                        <td rowspan="1" colspan="1">46 (49.5)</td>
                        <td rowspan="1" colspan="1">156 (47.9)</td>
                        <td rowspan="1" colspan="1">61 (22.7)</td>
                      </tr>
                      <tr>
                        <td rowspan="1" colspan="1">ȃVaginal insertion ever reported in trial</td>
                        <td rowspan="1" colspan="1">124 (18)</td>
                        <td rowspan="1" colspan="1">9 (9.7)</td>
                        <td rowspan="1" colspan="1">53 (16.3)</td>
                        <td rowspan="1" colspan="1">62 (23)</td>
                      </tr>
                      <tr>
                        <td rowspan="1" colspan="1">ȃCondom use</td>
                        <td rowspan="1" colspan="1"/>
                        <td rowspan="1" colspan="1"/>
                        <td rowspan="1" colspan="1"/>
                        <td rowspan="1" colspan="1"/>
                      </tr>
                      <tr>
                        <td rowspan="1" colspan="1">ȃȃAlways</td>
                        <td rowspan="1" colspan="1">198 (28.8)</td>
                        <td rowspan="1" colspan="1">25 (26.9)</td>
                        <td rowspan="1" colspan="1">98 (30.1)</td>
                        <td rowspan="1" colspan="1">75 (27.9)</td>
                      </tr>
                      <tr>
                        <td rowspan="1" colspan="1">ȃȃMost times</td>
                        <td rowspan="1" colspan="1">126 (18.3)</td>
                        <td rowspan="1" colspan="1">15 (16.1)</td>
                        <td rowspan="1" colspan="1">65 (19.9)</td>
                        <td rowspan="1" colspan="1">46 (17.1)</td>
                      </tr>
                      <tr>
                        <td rowspan="1" colspan="1">ȃȃOccasionally</td>
                        <td rowspan="1" colspan="1">251 (36.5)</td>
                        <td rowspan="1" colspan="1">33 (35.5)</td>
                        <td rowspan="1" colspan="1">122 (37.4)</td>
                        <td rowspan="1" colspan="1">96 (35.7)</td>
                      </tr>
                      <tr>
                        <td rowspan="1" colspan="1">ȃȃNever</td>
                        <td rowspan="1" colspan="1">113 (16.4)</td>
                        <td rowspan="1" colspan="1">20 (21.5)</td>
                        <td rowspan="1" colspan="1">41 (12.6)</td>
                        <td rowspan="1" colspan="1">52 (19.3)</td>
                      </tr>
                      <tr>
                        <td rowspan="1" colspan="1">Demographics and characteristics at time of sample collection</td>
                        <td rowspan="1" colspan="1"/>
                        <td rowspan="1" colspan="1"/>
                        <td rowspan="1" colspan="1"/>
                        <td rowspan="1" colspan="1"/>
                      </tr>
                      <tr>
                        <td rowspan="1" colspan="1">ȃ<italic toggle="yes">Lactobacillus</italic> dominant</td>
                        <td rowspan="1" colspan="1">408 (59.3)</td>
                        <td rowspan="1" colspan="1">49 (52.7)</td>
                        <td rowspan="1" colspan="1">185 (56.7)</td>
                        <td rowspan="1" colspan="1">174 (64.7)</td>
                      </tr>
                      <tr>
                        <td rowspan="1" colspan="1">ȃContraception use<sup><xref rid="ciac938-tblfn5" ref-type="table-fn">c</xref></sup></td>
                        <td rowspan="1" colspan="1"/>
                        <td rowspan="1" colspan="1"/>
                        <td rowspan="1" colspan="1"/>
                        <td rowspan="1" colspan="1"/>
                      </tr>
                      <tr>
                        <td rowspan="1" colspan="1">ȃȃDMPA</td>
                        <td rowspan="1" colspan="1">450 (65.4)</td>
                        <td rowspan="1" colspan="1">70 (75.3)</td>
                        <td rowspan="1" colspan="1">217 (66.6)</td>
                        <td rowspan="1" colspan="1">163 (60.6)</td>
                      </tr>
                      <tr>
                        <td rowspan="1" colspan="1">ȃȃNET-EN</td>
                        <td rowspan="1" colspan="1">123 (17.9)</td>
                        <td rowspan="1" colspan="1">16 (17.2)</td>
                        <td rowspan="1" colspan="1">63 (19.3)</td>
                        <td rowspan="1" colspan="1">44 (16.4)</td>
                      </tr>
                      <tr>
                        <td rowspan="1" colspan="1">ȃȃCOC</td>
                        <td rowspan="1" colspan="1">96 (14)</td>
                        <td rowspan="1" colspan="1">6 (6.5)</td>
                        <td rowspan="1" colspan="1">40 (12.3)</td>
                        <td rowspan="1" colspan="1">50 (18.6)</td>
                      </tr>
                      <tr>
                        <td rowspan="1" colspan="1">ȃȃOther</td>
                        <td rowspan="1" colspan="1">16 (2.3)</td>
                        <td rowspan="1" colspan="1">0 (0)</td>
                        <td rowspan="1" colspan="1">4 (1.2)</td>
                        <td rowspan="1" colspan="1">12 (4.5)</td>
                      </tr>
                      <tr>
                        <td rowspan="1" colspan="1">ȃVaginal discharge<sup><xref rid="ciac938-tblfn6" ref-type="table-fn">d</xref></sup></td>
                        <td rowspan="1" colspan="1">50 (7.3)</td>
                        <td rowspan="1" colspan="1">3 (3.2)</td>
                        <td rowspan="1" colspan="1">31 (9.5)</td>
                        <td rowspan="1" colspan="1">16 (5.9)</td>
                      </tr>
                      <tr>
                        <td rowspan="1" colspan="1">ȃAny cervical ectopy<sup><xref rid="ciac938-tblfn7" ref-type="table-fn">e</xref></sup></td>
                        <td rowspan="1" colspan="1">49 (7.1)</td>
                        <td rowspan="1" colspan="1">3 (3.2)</td>
                        <td rowspan="1" colspan="1">29 (8.9)</td>
                        <td rowspan="1" colspan="1">17 (6.3)</td>
                      </tr>
                      <tr>
                        <td rowspan="1" colspan="1">ȃVaginal insertion at visit</td>
                        <td rowspan="1" colspan="1">33 (4.8)</td>
                        <td rowspan="1" colspan="1">2 (2.2)</td>
                        <td rowspan="1" colspan="1">20 (6.1)</td>
                        <td rowspan="1" colspan="1">11 (4.1)</td>
                      </tr>
                      <tr>
                        <td rowspan="1" colspan="1">ȃAntibiotic use in past 30 d</td>
                        <td rowspan="1" colspan="1">54 (7.8)</td>
                        <td rowspan="1" colspan="1">8 (8.6)</td>
                        <td rowspan="1" colspan="1">23 (7.1)</td>
                        <td rowspan="1" colspan="1">23 (8.6)</td>
                      </tr>
                      <tr>
                        <td rowspan="1" colspan="1">ȃSex acts in past 30 d, mean ± SD; range<sup><xref rid="ciac938-tblfn8" ref-type="table-fn">f</xref></sup></td>
                        <td rowspan="1" colspan="1">5.6 ± 5.2; 0–42</td>
                        <td rowspan="1" colspan="1">6.1 ± 5.6; 0–28</td>
                        <td rowspan="1" colspan="1">5.1 ± 4.5; 0–22</td>
                        <td rowspan="1" colspan="1">6 ± 5.9; 0–42</td>
                      </tr>
                      <tr>
                        <td rowspan="1" colspan="1">ȃMedian adherence during trial &gt;50%</td>
                        <td rowspan="1" colspan="1">418 (60.8)</td>
                        <td rowspan="1" colspan="1">45 (48.4)</td>
                        <td rowspan="1" colspan="1">194 (59.5)</td>
                        <td rowspan="1" colspan="1">179 (66.5)</td>
                      </tr>
                    </tbody>
                  </table>
                  <table-wrap-foot>
                    <fn id="ciac938-tblfn1">
                      <p>Data are presented as No. (%) unless otherwise indicated.</p>
                    </fn>
                    <fn id="ciac938-tblfn2">
                      <p>Abbreviations: COC, combined oral contraceptive; DMPA, deoxymedroxyprogesterone acetate; HIV, human immunodeficiency virus; HSV-2, herpes simplex virus type 2; NET-EN, norethisterone enanthate; SD, standard deviation; STI, sexually transmitted infection; TFV, tenofovir.</p>
                    </fn>
                    <fn id="ciac938-tblfn3">
                      <p>Three hundred nine individuals did not have information available on STIs tested during the trial.</p>
                    </fn>
                    <fn id="ciac938-tblfn4">
                      <p>Seven individuals had inconclusive or no results for HSV-2 testing.</p>
                    </fn>
                    <fn id="ciac938-tblfn5">
                      <p>Three individuals did not provide information on contraceptive use at the visit of sample collection.</p>
                    </fn>
                    <fn id="ciac938-tblfn6">
                      <p>Three individuals did not have information available on vaginal discharges at the visit.</p>
                    </fn>
                    <fn id="ciac938-tblfn7">
                      <p>Twenty-four individuals did not provide information on cervical ectopy at the visit.</p>
                    </fn>
                    <fn id="ciac938-tblfn8">
                      <p>Three individuals did not have information available on sexual activity in the past 30 days.</p>
                    </fn>
                  </table-wrap-foot>
                </table-wrap>
              </sec>
              <sec id="ciac938-s1.2">
                <title>Vaginal Metaproteomic Analysis Identifies 4 Major Bacterial Community State Types</title>
                <p>Metaproteomics analysis was used to identify the microbial composition of cervicovaginal lavage samples as previously reported [<xref rid="ciac938-B24" ref-type="bibr">24</xref>]. At the genus level, the most abundant taxa included <italic toggle="yes">Lactobacillus</italic> (52.3%), <italic toggle="yes">Gardnerella</italic> (24.3%), <italic toggle="yes">Prevotella</italic> (4.9%), <italic toggle="yes">Pseudomonas</italic> (4.0%), and <italic toggle="yes">Mobiluncus</italic> (3.2%). As <italic toggle="yes">Lactobacillus iners</italic> and <italic toggle="yes">L. crispatus</italic> species comprised most of the genus (30.4% and 12.9% of all <italic toggle="yes">Lactobacillus</italic> proteins, respectively), <italic toggle="yes">Lactobacillus</italic> was clustered at the species level. Four major community state types (CSTs) were identified based on the predominant taxa, including CST-LC (<italic toggle="yes">L. crispatus</italic>), CST-LI (<italic toggle="yes">L. iners</italic>), CST-GV (<italic toggle="yes">Gardnerella vaginalis</italic>), and CST-PM (polymicrobial species) (<xref rid="ciac938-F1" ref-type="fig">Figure 1<italic toggle="yes">A</italic></xref>
). A minor CST subgroup was also identified, CST-LS, which was <italic toggle="yes">Lactobacillus</italic> dominant (LD) but could not be discerned to the species level. CST-LI was most predominant at 43.6%, followed by CST-GV at 26.6%, CST-PM at 15.1%, CST-LC at 12.2%, and CST-LS at 2.5%. Participants with &gt;50% of bacterial proteins belonging to a <italic toggle="yes">Lactobacillus</italic> species were categorized as LD, and those with &lt;50% were categorized as non-<italic toggle="yes">Lactobacillus</italic> dominant (nLD). More participants were LD than nLD (59.3% and 40.7%, respectively).</p>
                <fig position="float" id="ciac938-F1" fig-type="figure">
                  <label>Figure 1.</label>
                  <caption>
                    <p>Major vaginal microbiome community state types (CSTs) in study participants as identified by metaproteomic analysis. <italic toggle="yes">A</italic>, Stacked bar plot demonstrates bacterial composition of each CST (LC = <italic toggle="yes">Lactobacillus crispatus</italic> dominant, n = 84; LI = <italic toggle="yes">Lactobacillus iners</italic> dominant, n = 300; GV = <italic toggle="yes">Gardnerella vaginalis</italic> dominant, n = 183; PM = polymicrobial, n = 104). Proportions of the most abundant (&gt;5%) bacterial taxa per CST are shown as percentages. <italic toggle="yes">B</italic>, Box-and-whisker plots represent distribution of α-diversities (Shannon H index) across CSTs. A small subset of samples (n = 17, <italic toggle="yes">Lactobacillus</italic> spp dominant) were not resolvable to the species level precluding diversity estimates, and therefore this group was not included.</p>
                  </caption>
                  <graphic xlink:href="ciac938f1" position="float"/>
                </fig>
                <p>CST-LC had the lowest diversity (mean Shannon diversity index [H] = 0.12) where <italic toggle="yes">L. crispatus</italic> made up 70.2% of the total protein identified, with smaller amounts of indiscernible <italic toggle="yes">Lactobacillus</italic> species (17.8%) and <italic toggle="yes">L. iners</italic> (6.4%) (<xref rid="ciac938-F1" ref-type="fig">Figure 1<italic toggle="yes">B</italic></xref>
). CST-LI was also low diversity (mean H = 0.12), where <italic toggle="yes">L. iners</italic> comprised 80.4% of the overall taxa, with smaller amounts of indiscernible <italic toggle="yes">Lactobacillus</italic> species (11.4%), <italic toggle="yes">L. crispatus</italic> (3.7%), and <italic toggle="yes">G. vaginalis</italic> (1.83%). As the CST-LS group could not be distinguished to the species level, the diversity estimate was not calculated. In contrast, those with non-<italic toggle="yes">Lactobacillus</italic> bacteria showed higher diversity, including CST-GV (mean H = 0.70), where <italic toggle="yes">G. vaginalis</italic> was predominant (66.8%), with minor amounts from <italic toggle="yes">Prevotella</italic> (4.2%), <italic toggle="yes">L. iners</italic> (3.2%), and indiscernible <italic toggle="yes">Lactobacillus</italic> species (1.8%). CST-PM was the most diverse (mean H = 0.95) with no dominant taxa; where <italic toggle="yes">G. vaginalis</italic> (20.0%), <italic toggle="yes">Prevotella</italic> (13.6%), <italic toggle="yes">Pseudomonas</italic> (12.8%), and <italic toggle="yes">Mobiluncus</italic> (12.1%) were similarly abundant.</p>
              </sec>
              <sec id="ciac938-s1.3">
                <title>Polymicrobial and <italic toggle="yes">Lactobacillus</italic>-Depleted Bacterial Metaproteomes Are Increased in 18- and 19-Year-Old Women</title>
                <p>We then assessed microbial composition among age groups. The LD/nLD ratio increased with age, driven largely by increasing CST-LI microbiomes, with decreasing CST-GV and CST-PM microbiomes (<xref rid="ciac938-F2" ref-type="fig">Figure 2<italic toggle="yes">A</italic></xref>
). Compared to women aged 25–41 years, those in the age groups 18–19 years and 20–24 years were more likely to have an nLD microbiome (odds ratio [OR], 1.65 [95% confidence interval {CI}, 1.02–2.65], <italic toggle="yes">P</italic> = .028; OR, 1.40 [95% CI, 1.01–1.95], <italic toggle="yes">P</italic> = .030, respectively) (<xref rid="ciac938-F2" ref-type="fig">Figure 2<italic toggle="yes">B</italic></xref>
) and CST-PM relative to a CST-LC microbiome (OR, 3.14 [95% CI, 1.12–7.87], <italic toggle="yes">P</italic> = .017; OR, 2.81 [95% CI, 1.07–7.09], <italic toggle="yes">P</italic> = .038, respectively) (<xref rid="ciac938-F2" ref-type="fig">Figure 2<italic toggle="yes">C</italic></xref>
). Except for CST-PM, the distributions of other CSTs relative to CST-LC were similar across age groups. At the genus level, we observed an increasing proportion of BVAB, including <italic toggle="yes">Megasphaera</italic> (<italic toggle="yes">r</italic> = −0.087, <italic toggle="yes">P</italic> = .023, adjusted <italic toggle="yes">P</italic> = .45) and <italic toggle="yes">Atopobium</italic> (<italic toggle="yes">r</italic> = −0.075, <italic toggle="yes">P</italic> = .0495, adjusted <italic toggle="yes">P</italic> = .45), with decreasing age. However, only <italic toggle="yes">Megasphaera</italic> was more prevalent in women aged 18–19 years compared to those aged 25–41 years (log<sub>2</sub> fold difference = 1.72, <italic toggle="yes">P</italic> = .0023, adjusted <italic toggle="yes">P</italic> = .0498). Younger age was also associated with increased prevalence of inflammatory bacterial pathways, including propanoate (<italic toggle="yes">r</italic> = −0.090, <italic toggle="yes">P</italic> = .020, adjusted <italic toggle="yes">P</italic> = .41) and butanoate metabolism (<italic toggle="yes">r</italic> = −0.086, <italic toggle="yes">P</italic> = .027, adjusted <italic toggle="yes">P</italic> = .41). In a multivariable logistic regression analysis to control for differences in clinical, behavioral, and demographic variables (<xref rid="ciac938-T2" ref-type="table">Table 2</xref>), nLD vaginal microbiomes remained significantly higher in the age groups 18–19 years and 20–24 years (OR, 2.08 [95% CI, 1.28–3.54], <italic toggle="yes">P</italic> = .007; OR, 1.67 [95% CI, 1.16–2.42], <italic toggle="yes">P</italic> = .006, respectively). HSV-2 infection at baseline was associated with increased non-<italic toggle="yes">Lactobacillus</italic> microbiomes, but HSV-2 infection was much lower in younger age groups (<xref rid="ciac938-T1" ref-type="table">Table 1</xref>), and non-<italic toggle="yes">Lactobacillus</italic> microbiomes remained higher in women aged 18–19 years and 20–24 years when stratified into HSV-2–seropositive (OR, 1.97 [95% CI, .88–4.33], <italic toggle="yes">P</italic> = .0628; OR, 1.58 [95% CI, .4–2.51], <italic toggle="yes">P</italic> = .0272, respectively) or HSV-2–seronegative groups (OR, 2.083 [95% CI, 1.01–4.16], <italic toggle="yes">P</italic> = .0331; OR, 1.68 [95% CI, .92–3.04], <italic toggle="yes">P</italic> = .0546, respectively). DMPA use was associated with decreased non-<italic toggle="yes">Lactobacillus</italic> microbiomes in a multivariate model. However, younger women reported increased usage of DMPA, and a further subanalysis using serum medroxyprogesterone actetate (MPA) levels, which we measured previously [<xref rid="ciac938-B26" ref-type="bibr">26</xref>] (<xref rid="sup1" ref-type="supplementary-material">Supplementary Methods</xref>), showed that higher MPA was associated with lower non-<italic toggle="yes">Lactobacillus</italic> microbiomes (high/medium vs low/undetectable MPA: OR, 0.705 [95% CI, .48–1.05], <italic toggle="yes">P</italic> = .075), which was not statistically significant. Overall, differences in these variables could not explain increased non-<italic toggle="yes">Lactobacillus</italic> microbiomes in younger women.</p>
                <fig position="float" id="ciac938-F2" fig-type="figure">
                  <label>Figure 2.</label>
                  <caption>
                    <p>Vaginal bacterial metaproteome profiles of study participants stratified by age group. <italic toggle="yes">A</italic>, Proportions of bacterial taxa and functional pathways are displayed for each age group: 18–19 (n = 93), 20–24 (n = 326), and 25–41 (n = 269) years. Stacked bar plots are annotated with <italic toggle="yes">Lactobacillus</italic> dominance status and community state type (CST) categorization. <italic toggle="yes">B</italic>, Proportion of <italic toggle="yes">Lactobacillus</italic>-/non-<italic toggle="yes">Lactobacillus</italic>-dominant status between age groups were assessed for statistical significance using Fisher exact test. <italic toggle="yes">C</italic>, Proportions of CST-polymicrobial relative to CST–<italic toggle="yes">Lactobacillus crispatus</italic> dominant between age groups were assessed for statistical significance using Fisher exact test. Abbreviations: CST, community state type; GV, <italic toggle="yes">Gardnerella vaginalis</italic> dominant; LC, <italic toggle="yes">Lactobacillus crispatus</italic> dominant; LD, <italic toggle="yes">Lactobacillus</italic> dominant; LI, <italic toggle="yes">Lactobacillus iners</italic> dominant; LS, <italic toggle="yes">Lactobacillus</italic> species dominant; nLD, non-<italic toggle="yes">Lactobacillus</italic> dominant; OR, odds ratio; PM, polymicrobial.</p>
                  </caption>
                  <graphic xlink:href="ciac938f2" position="float"/>
                </fig>
                <table-wrap position="float" id="ciac938-T2">
                  <label>Table 2.</label>
                  <caption>
                    <p>Adjusted Logistic Regression Model Estimates of Non-<italic toggle="yes">Lactobacillus</italic> Vaginal Microbiome Dominance Risk Associated With Age Groups</p>
                  </caption>
                  <table frame="hsides" rules="groups">
                    <colgroup span="1">
                      <col valign="top" align="left" span="1"/>
                      <col valign="top" align="center" span="1"/>
                      <col valign="top" align="left" span="1"/>
                      <col valign="top" align="center" span="1"/>
                      <col valign="top" align="center" span="1"/>
                      <col valign="top" align="left" span="1"/>
                      <col valign="top" align="center" span="1"/>
                    </colgroup>
                    <thead>
                      <tr>
                        <th rowspan="2" align="left" colspan="1">Model</th>
                        <th colspan="3" align="center" rowspan="1">Univariate</th>
                        <th colspan="3" align="center" rowspan="1">Multivariable</th>
                      </tr>
                      <tr>
                        <th align="left" rowspan="1" colspan="1">OR</th>
                        <th align="center" rowspan="1" colspan="1">(95% CI)</th>
                        <th align="center" rowspan="1" colspan="1"><italic toggle="yes">P</italic> Value</th>
                        <th align="center" rowspan="1" colspan="1">OR</th>
                        <th align="center" rowspan="1" colspan="1">(95% CI)</th>
                        <th align="center" rowspan="1" colspan="1"><italic toggle="yes">P</italic> Value</th>
                      </tr>
                    </thead>
                    <tbody>
                      <tr>
                        <td rowspan="1" colspan="1">Age group (18–19 y vs 25–41 y)</td>
                        <td rowspan="1" colspan="1">1.64</td>
                        <td rowspan="1" colspan="1">(1.02–2.65)</td>
                        <td rowspan="1" colspan="1">.041</td>
                        <td rowspan="1" colspan="1">2.08</td>
                        <td rowspan="1" colspan="1">(1.28–3.54)</td>
                        <td rowspan="1" colspan="1">.007</td>
                      </tr>
                      <tr>
                        <td rowspan="1" colspan="1">Age group (20–24 y vs 25–41 y)</td>
                        <td rowspan="1" colspan="1">1.40</td>
                        <td rowspan="1" colspan="1">(1.00–1.95)</td>
                        <td rowspan="1" colspan="1">.049</td>
                        <td rowspan="1" colspan="1">1.67</td>
                        <td rowspan="1" colspan="1">(1.16–2.42)</td>
                        <td rowspan="1" colspan="1">.006</td>
                      </tr>
                      <tr>
                        <td rowspan="1" colspan="1">Study arm (tenofovir vs placebo)</td>
                        <td rowspan="1" colspan="1">1.02</td>
                        <td rowspan="1" colspan="1">(.75–1.38)</td>
                        <td rowspan="1" colspan="1">.904</td>
                        <td rowspan="1" colspan="1">0.96</td>
                        <td rowspan="1" colspan="1">(.70–1.32)</td>
                        <td rowspan="1" colspan="1">.807</td>
                      </tr>
                      <tr>
                        <td rowspan="1" colspan="1">Study site (urban vs rural)</td>
                        <td rowspan="1" colspan="1">0.79</td>
                        <td rowspan="1" colspan="1">(.56–1.11)</td>
                        <td rowspan="1" colspan="1">.179</td>
                        <td rowspan="1" colspan="1">0.77</td>
                        <td rowspan="1" colspan="1">(.45–1.32)</td>
                        <td rowspan="1" colspan="1">.350</td>
                      </tr>
                      <tr>
                        <td rowspan="1" colspan="1">HSV-2 at baseline (seropositive vs seronegative)</td>
                        <td rowspan="1" colspan="1">1.34</td>
                        <td rowspan="1" colspan="1">(.98–1.82)</td>
                        <td rowspan="1" colspan="1">.064</td>
                        <td rowspan="1" colspan="1">1.65</td>
                        <td rowspan="1" colspan="1">(1.17–2.32)</td>
                        <td rowspan="1" colspan="1">.004</td>
                      </tr>
                      <tr>
                        <td rowspan="1" colspan="1">Contraceptive (DMPA use vs non-DMPA use)</td>
                        <td rowspan="1" colspan="1">0.75</td>
                        <td rowspan="1" colspan="1">(.55–1.04)</td>
                        <td rowspan="1" colspan="1">.082</td>
                        <td rowspan="1" colspan="1">0.64</td>
                        <td rowspan="1" colspan="1">(.45–.91)</td>
                        <td rowspan="1" colspan="1">.012</td>
                      </tr>
                      <tr>
                        <td rowspan="1" colspan="1">Given birth (yes vs no)</td>
                        <td rowspan="1" colspan="1">1.05</td>
                        <td rowspan="1" colspan="1">(.72–1.54)</td>
                        <td rowspan="1" colspan="1">.790</td>
                        <td rowspan="1" colspan="1">1.28</td>
                        <td rowspan="1" colspan="1">(.85–1.94)</td>
                        <td rowspan="1" colspan="1">.247</td>
                      </tr>
                      <tr>
                        <td rowspan="1" colspan="1">Vaginal insertion history (yes vs no)</td>
                        <td rowspan="1" colspan="1">0.76</td>
                        <td rowspan="1" colspan="1">(.51–1.14)</td>
                        <td rowspan="1" colspan="1">.193</td>
                        <td rowspan="1" colspan="1">0.89</td>
                        <td rowspan="1" colspan="1">(.49–1.65)</td>
                        <td rowspan="1" colspan="1">.715</td>
                      </tr>
                      <tr>
                        <td rowspan="1" colspan="1">Sex acts in past 30 d</td>
                        <td rowspan="1" colspan="1">0.97</td>
                        <td rowspan="1" colspan="1">(.94–1.00)</td>
                        <td rowspan="1" colspan="1">.078</td>
                        <td rowspan="1" colspan="1">0.98</td>
                        <td rowspan="1" colspan="1">(.95–1.01)</td>
                        <td rowspan="1" colspan="1">.207</td>
                      </tr>
                    </tbody>
                  </table>
                  <table-wrap-foot>
                    <fn id="ciac938-tblfn12">
                      <p>Abbreviations: CI, confidence interval; DMPA, deoxymedroxyprogesterone acetate; HSV-2, herpes simplex virus type 2; OR, odds ratio.</p>
                    </fn>
                  </table-wrap-foot>
                </table-wrap>
              </sec>
              <sec id="ciac938-s1.4">
                <title>Polymicrobial and <italic toggle="yes">Lactobacillus-</italic>Depleted Vaginal Bacterial Metaproteomes Are Associated With Increased HIV Acquisition</title>
                <p>We next evaluated the relationship between the vaginal microbiome and HIV acquisition risk. In this analysis we only included CST-LC, CST-LI, CST-GV, and CST-PM given there were few individuals (n = 17) and cases (n = 4) in CST-LS. Demographic characteristics of CST groupings are shown in <xref rid="sup1" ref-type="supplementary-material">Supplementary Table 1</xref>.</p>
                <p>The proportion of HIV cases was lowest in CST-LC (n = 3 [3.6%]) and highest in CST-PM (n = 22 [21.2%]) (<xref rid="ciac938-F3" ref-type="fig">Figure 3</xref>). The probability of HIV acquisition was 7.19-fold higher in women in CST-PM than in CST-LC (hazard ratio [HR], 7.19 [95% CI, 2.11–24.5], <italic toggle="yes">P</italic> = .00162; <xref rid="ciac938-F3" ref-type="fig">Figure 3<italic toggle="yes">A</italic></xref>
). The rate of HIV acquisition was 2.28-fold higher in women in CST-LI (HR, 2.28 [95% CI, .69–7.57], <italic toggle="yes">P</italic> = .179) and 1.22-fold higher in CST-GV (HR, 1.22 [95% CI, .32–4.61], <italic toggle="yes">P</italic> = .765) in all women, but these were not statistically significant. Adjustment for baseline variables that are unevenly distributed between CST-LC and CST-PM and/or could modulate HIV infection did not significantly impact these findings (adjusted HR, 5.66 [95% CI, 1.58–20.24], <italic toggle="yes">P</italic> = .0077; <xref rid="ciac938-T3" ref-type="table">Table 3</xref>). When stratified by age, increased risks of HIV acquisition in CST-PM relative to CST-LC were observed for women aged 20–24 years (HR, 4.90 [95% CI, 1.10–21.9], <italic toggle="yes">P</italic> = .0375; <xref rid="sup1" ref-type="supplementary-material">Supplementary Figure 1</xref>). In the age group 18–19 years, due to smaller sample size, there were few HIV seroconversion events (8 infections), which limited power to analyze relative HIV incidence between CSTs. In the age group 25–41 years there were no infections in CST-LC (0/37), which precluded a hazard ratio analysis, although in CST-PM 8 of 24 (25%) were cases.</p>
                <fig position="float" id="ciac938-F3" fig-type="figure">
                  <label>Figure 3.</label>
                  <caption>
                    <p>Cumulative human immunodeficiency virus (HIV) infection probability by vaginal bacterial community state type (CST). <italic toggle="yes">A</italic>, Kaplan-Meier curve demonstrates HIV infections per CST over time. Infection rates within CSTs <italic toggle="yes">Lactobacillus iners</italic> dominant (LI), <italic toggle="yes">Gardnerella vaginalis</italic> dominant (GV), and polymicrobial (PM) relative to CST–<italic toggle="yes">Lactobacillus crispatus</italic> dominant (LC) are assessed using the Cox proportional hazards model with hazard ratios (HRs) displayed. As there were very few participants in the CST–<italic toggle="yes">Lactobacillus</italic> spp-dominant (n = 17) microbiome group, resulting in limited power, it was not included in this HIV risk analysis. <italic toggle="yes">B</italic>, Percentages of HIV seroconversion across CSTs are shown. Fisher exact test–based <italic toggle="yes">P</italic> value is shown for seroconversion rates that differ significantly between CSTs. Number and percentage of individuals who did or did not acquire HIV are displayed.</p>
                  </caption>
                  <graphic xlink:href="ciac938f3" position="float"/>
                </fig>
                <table-wrap position="float" id="ciac938-T3">
                  <label>Table 3.</label>
                  <caption>
                    <p>Adjusted Estimates for Human Immunodeficiency Virus Risk Associated With Community State Type (CST)–Polymicrobial Relative to CST–<italic toggle="yes">Lactobacillus crispatus</italic> Vaginal Microbiomes</p>
                  </caption>
                  <table frame="hsides" rules="groups">
                    <colgroup span="1">
                      <col valign="top" align="left" span="1"/>
                      <col valign="top" align="center" span="1"/>
                      <col valign="top" align="left" span="1"/>
                      <col valign="top" align="center" span="1"/>
                      <col valign="top" align="center" span="1"/>
                      <col valign="top" align="left" span="1"/>
                      <col valign="top" align="center" span="1"/>
                    </colgroup>
                    <thead>
                      <tr>
                        <th rowspan="2" align="left" colspan="1">Model</th>
                        <th colspan="3" align="center" rowspan="1">Univariate</th>
                        <th colspan="3" align="center" rowspan="1">Multivariable</th>
                      </tr>
                      <tr>
                        <th align="left" rowspan="1" colspan="1">HR</th>
                        <th align="center" rowspan="1" colspan="1">(95% CI)</th>
                        <th align="center" rowspan="1" colspan="1"><italic toggle="yes">P</italic> Value</th>
                        <th align="center" rowspan="1" colspan="1">HR</th>
                        <th align="center" rowspan="1" colspan="1">(95% CI)</th>
                        <th align="center" rowspan="1" colspan="1"><italic toggle="yes">P</italic> Value</th>
                      </tr>
                    </thead>
                    <tbody>
                      <tr>
                        <td rowspan="1" colspan="1">Polymicrobial vs <italic toggle="yes">Lactobacillus crispatus</italic> microbiome</td>
                        <td rowspan="1" colspan="1">7.19</td>
                        <td rowspan="1" colspan="1">(2.11–24.5)</td>
                        <td rowspan="1" colspan="1">.0016</td>
                        <td rowspan="1" colspan="1">5.66</td>
                        <td rowspan="1" colspan="1">(1.58–20.24)</td>
                        <td rowspan="1" colspan="1">.0077</td>
                      </tr>
                      <tr>
                        <td rowspan="1" colspan="1">Study arm (tenofovir vs placebo)</td>
                        <td rowspan="1" colspan="1">0.97</td>
                        <td rowspan="1" colspan="1">(.44–2.14)</td>
                        <td rowspan="1" colspan="1">.9416</td>
                        <td rowspan="1" colspan="1">0.8</td>
                        <td rowspan="1" colspan="1">(.33–1.95)</td>
                        <td rowspan="1" colspan="1">.6187</td>
                      </tr>
                      <tr>
                        <td rowspan="1" colspan="1">Median adherence &gt;50% (yes vs no)</td>
                        <td rowspan="1" colspan="1">1.54</td>
                        <td rowspan="1" colspan="1">(.66–3.59)</td>
                        <td rowspan="1" colspan="1">.3147</td>
                        <td rowspan="1" colspan="1">1.14</td>
                        <td rowspan="1" colspan="1">(.42–3.06)</td>
                        <td rowspan="1" colspan="1">.7945</td>
                      </tr>
                      <tr>
                        <td rowspan="1" colspan="1">Study site (urban vs rural)</td>
                        <td rowspan="1" colspan="1">0.99</td>
                        <td rowspan="1" colspan="1">(.41–2.39)</td>
                        <td rowspan="1" colspan="1">.9840</td>
                        <td rowspan="1" colspan="1">1.05</td>
                        <td rowspan="1" colspan="1">(.34–3.24)</td>
                        <td rowspan="1" colspan="1">.9286</td>
                      </tr>
                      <tr>
                        <td rowspan="1" colspan="1">HSV-2 at baseline (seropositive vs seronegative)</td>
                        <td rowspan="1" colspan="1">1.80</td>
                        <td rowspan="1" colspan="1">(.76–4.27)</td>
                        <td rowspan="1" colspan="1">.1827</td>
                        <td rowspan="1" colspan="1">2.26</td>
                        <td rowspan="1" colspan="1">(.87–5.90)</td>
                        <td rowspan="1" colspan="1">.9540</td>
                      </tr>
                      <tr>
                        <td rowspan="1" colspan="1">Contraceptive (DMPA use vs non-DMPA use)</td>
                        <td rowspan="1" colspan="1">1.14</td>
                        <td rowspan="1" colspan="1">(.49–2.64)</td>
                        <td rowspan="1" colspan="1">.7654</td>
                        <td rowspan="1" colspan="1">1.53</td>
                        <td rowspan="1" colspan="1">(.55–4.24)</td>
                        <td rowspan="1" colspan="1">.4182</td>
                      </tr>
                      <tr>
                        <td rowspan="1" colspan="1">Condom use (occasionally/never vs always/most times)</td>
                        <td rowspan="1" colspan="1">1.23</td>
                        <td rowspan="1" colspan="1">(.56–2.71)</td>
                        <td rowspan="1" colspan="1">.6083</td>
                        <td rowspan="1" colspan="1">1.34</td>
                        <td rowspan="1" colspan="1">(.56–3.26)</td>
                        <td rowspan="1" colspan="1">.5115</td>
                      </tr>
                      <tr>
                        <td rowspan="1" colspan="1">No. of sexual partners</td>
                        <td rowspan="1" colspan="1">0.83</td>
                        <td rowspan="1" colspan="1">(.60–1.16)</td>
                        <td rowspan="1" colspan="1">.2868</td>
                        <td rowspan="1" colspan="1">0.79</td>
                        <td rowspan="1" colspan="1">(.53–1.16)</td>
                        <td rowspan="1" colspan="1">.2315</td>
                      </tr>
                      <tr>
                        <td rowspan="1" colspan="1">Sex acts in past 30 d</td>
                        <td rowspan="1" colspan="1">0.97</td>
                        <td rowspan="1" colspan="1">(.89–1.06)</td>
                        <td rowspan="1" colspan="1">.5122</td>
                        <td rowspan="1" colspan="1">1.00</td>
                        <td rowspan="1" colspan="1">(.90–1.10)</td>
                        <td rowspan="1" colspan="1">.9668</td>
                      </tr>
                    </tbody>
                  </table>
                  <table-wrap-foot>
                    <fn id="ciac938-tblfn13">
                      <p>Abbreviations: CI, confidence interval; DMPA, deoxymedroxyprogesterone acetate; HR, hazard ratio; HSV-2, herpes simplex virus type 2.</p>
                    </fn>
                  </table-wrap-foot>
                </table-wrap>
              </sec>
            </sec>
            <sec sec-type="discussion" id="ciac938-s2">
              <title>DISCUSSION</title>
              <p>Young women and adolescent girls are a predominant high-risk group for new HIV infections in sub-Saharan Africa. In this study we show that women aged 18–19 years in a highly representative at-risk population in an HIV prevention trial setting have significantly higher proportion of <italic toggle="yes">Lactobacillus-</italic>depleted and polymicrobial vaginal microbiomes than their older counterparts. Furthermore, we show that polymicrobial microbiomes are independently predictive of &gt;7-fold increased HIV acquisition than women with <italic toggle="yes">L. crispatus</italic>–dominant vaginal microbiomes. This collective data indicates that vaginal microbiome differences in younger women are likely a significant contributor to increased HIV susceptibility in this group.</p>
              <p>Previous studies have examined the relationship of the vaginal microbiome with HIV infection risk in women. In the Females Rising through Education, Support, and Health (FRESH) cohort study that included 237 South African women, HIV acquisition was increased in women with low levels of vaginal <italic toggle="yes">Lactobacillus</italic> [<xref rid="ciac938-B23" ref-type="bibr">23</xref>]. Women with <italic toggle="yes">L. iners</italic>, <italic toggle="yes">G. vaginalis</italic>, and polymicrobial microbiomes were at higher risk of HIV infection than women with <italic toggle="yes">L. crispatus</italic>, largely consistent with our observations in CAPRISA 004, although relative risk was more pronounced in the FRESH cohort. Also, recent studies have linked certain anaerobic bacterial species with increased HIV acquisition, including <italic toggle="yes">Parvimonas</italic>, <italic toggle="yes">Gamella</italic>, <italic toggle="yes">Mycoplasma</italic>, <italic toggle="yes">Leptotrichia/Snethia</italic>, and others [<xref rid="ciac938-B27" ref-type="bibr">27</xref>]. As our analysis did not detect as many lower-abundance species, we were unable to compare these results to our findings. Future studies examining how they relate to younger age groups in the South African setting would be an important next step.</p>
              <p>Several studies have examined interactions between young age and the vaginal microbiome with conflicting results. A study of 394 reproductive-aged women in North America reported no age–vaginal microbiome associations [<xref rid="ciac938-B17" ref-type="bibr">17</xref>], others reported lower <italic toggle="yes">Lactobacillus</italic> species in adolescent girls [<xref rid="ciac938-B15" ref-type="bibr">15</xref>], and others found relatively high <italic toggle="yes">Lactobacillus</italic> [<xref rid="ciac938-B28" ref-type="bibr">28</xref>] or <italic toggle="yes">L. iners</italic> in younger women [<xref rid="ciac938-B29" ref-type="bibr">29</xref>]. A substudy of women from the Vaginal and Oral Interventions to Control the Epidemic (VOICE) trial in South Africa showed lower levels of <italic toggle="yes">Lactobacillus</italic> in women aged &lt;25 years compared to &gt;25 years [<xref rid="ciac938-B16" ref-type="bibr">16</xref>], consistent with our findings. Age–microbiome relationships are clearly complex and likely influenced by the geographical context, the comparator group, and other considerations such as diet, sex behaviors, and other factors [<xref rid="ciac938-B16" ref-type="bibr">16</xref>].</p>
              <p>The vaginal microbiome profiles of women in CAPRISA 004 were like other studies of African women, where only a minority had <italic toggle="yes">L. crispatus</italic> (12.0%) as the dominant bacterium, and many did not have <italic toggle="yes">Lactobacillus</italic> (41%), and similar to studies conducted in Kenya, Tanzania, and other parts of South Africa [<xref rid="ciac938-B22" ref-type="bibr">22</xref>, <xref rid="ciac938-B30" ref-type="bibr">30–32</xref>]. In the FRESH cohort study in South Africa [<xref rid="ciac938-B21" ref-type="bibr">21</xref>], only 10% had low-diversity <italic toggle="yes">L. crispatus</italic> microbiomes, while a larger proportion were <italic toggle="yes">L. iners</italic>. In contrast, higher amounts of <italic toggle="yes">L. crispatus</italic> and other <italic toggle="yes">Lactobacillus</italic> species have been reported in North American studies, indicating the importance of geographical context [<xref rid="ciac938-B17" ref-type="bibr">17</xref>].</p>
              <p>Differences in the vaginal microbiome could contribute to increased HIV acquisition through multiple mechanisms by impacting mucosal immunity of the FGT. Non<italic toggle="yes">-Lactobacillus</italic> microbiomes are associated with increased proinflammatory cytokines and genital inflammation, activated T cells that are targets for HIV, epithelial barrier disruption, and increased activation of neutrophil pathways [<xref rid="ciac938-B33" ref-type="bibr">33</xref>]. Proinflammatory cytokines can activate and recruit target cells to the mucosal surface, which may provide easier targets for HIV infection [<xref rid="ciac938-B34" ref-type="bibr">34–36</xref>], and activated CD4<sup>+</sup> T cells are more productive for virus replication. Vaginal epithelial barrier disruption [<xref rid="ciac938-B18" ref-type="bibr">18</xref>, <xref rid="ciac938-B37" ref-type="bibr">37</xref>] may allow for easier virus penetration into submucosa where resident immune cells reside [<xref rid="ciac938-B38" ref-type="bibr">38</xref>]. Neutrophils, while important for innate immunity, can also produce proteases that disrupt the epithelial barrier [<xref rid="ciac938-B39" ref-type="bibr">39</xref>]. While it is unknown the degree by which each of these may contribute to HIV susceptibility, collectively they may provide an environment more conducive for viral penetration, replication, and infection.</p>
              <p>There are several limitations to this study. As this was a cross-sectional analysis, we were unable to evaluate how changes in the microbiome may impact these results. While our adjusted models incorporated differences in demographic characteristics between age groups, it is possible other characteristics not captured in this analysis may also have contributed to these observations. We also did not have information on sexual partners of study participants, which may have contributed to differences in HIV exposure rates. Also, other STIs, including human papillomavirus [<xref rid="ciac938-B40" ref-type="bibr">40</xref>], have been shown to contribute to increased risk of HIV acquisition, and relative contribution to microbial dysbiosis and HIV acquisition would be an important next step. Also, while this study utilized a validated mass spectrometry technique for microbiome analysis [<xref rid="ciac938-B18" ref-type="bibr">18</xref>, <xref rid="ciac938-B24" ref-type="bibr">24</xref>, <xref rid="ciac938-B32" ref-type="bibr">32</xref>], this may contribute to differences in CST grouping assignments compared with 16S ribosomal RNA sequencing [<xref rid="ciac938-B18" ref-type="bibr">18</xref>], as it reflects the functional aspects of the microbiome [<xref rid="ciac938-B32" ref-type="bibr">32</xref>, <xref rid="ciac938-B41" ref-type="bibr">41</xref>, <xref rid="ciac938-B42" ref-type="bibr">42</xref>], and lower-abundance species not captured by mass spectrometry may have affected HIV risk estimates. Although we found that hormonal contraceptive usage, such as DMPA, was not associated with significant differences in vaginal microbiota in younger women, similar to previous analysis [<xref rid="ciac938-B26" ref-type="bibr">26</xref>], it is possible other hormone levels, including estrogen, could play a role. Finally, as these results do not show a causal or mechanistic relationship between vaginal microbiota and HIV acquisition, these findings are limited to how much microbiome differences may be attributed to HIV infection.</p>
              <p>This study provides further insight into how biological differences in the vaginal mucosa may contribute to increased HIV acquisition in AGYW in South Africa, and further supports the vaginal microbiome as an important component for HIV prevention. Progress in the development of live biotherapeutic products from <italic toggle="yes">L. crispatus</italic> and other trials testing microbiome-based therapies to promote vaginal <italic toggle="yes">Lactobacillus</italic> are showing promise, and these strategies could be additional avenues to assist in HIV prevention [<xref rid="ciac938-B43" ref-type="bibr">43–45</xref>]. In addition, HIV prevention trials of vaccines and preexposure prophylaxis in women need to consider the vaginal microbiome as an important risk modifier that may undermine the protective effects of some of these interventions. Finally, while risk counseling, access to health services, condom usage, and other social-behavioral interventions are important, these data further support the need for integration of sexual and reproductive health services with HIV prevention in AGYW.</p>
            </sec>
            <sec sec-type="supplementary-material" id="ciac938-s3">
              <title>Supplementary Data</title>
              <p><xref rid="sup1" ref-type="supplementary-material">Supplementary materials</xref> are available at <italic toggle="yes">Clinical Infectious Diseases</italic> online. Consisting of data provided by the authors to benefit the reader, the posted materials are not copyedited and are the sole responsibility of the authors, so questions or comments should be addressed to the corresponding author.</p>
            </sec>
            <sec sec-type="supplementary-material">
              <title>Supplementary Material</title>
              <supplementary-material id="sup1" position="float" content-type="local-data">
                <label>ciac938_Supplementary_Data</label>
                <media xlink:href="ciac938_supplementary_data.zip">
                  <caption>
                    <p>Click here for additional data file.</p>
                  </caption>
                </media>
              </supplementary-material>
            </sec>
          </body>
          <back>
            <sec id="ciac938-s4">
              <title>Notes</title>
              <p><bold><italic toggle="yes">Author contributions.</italic></bold><sc>a. d.</sc> B., L. R. M., and L. N. R. designed the study. Y. W., L. N. R., M. P., S. K., K. B., R. M., and S. H. analyzed the data. Y. W., L. N. R., S. K., R. M., C. F., L. R. M., and <sc>a. d.</sc> B. wrote the manuscript.</p>
              <p><bold><italic toggle="yes">Acknowledgments.</italic></bold> The authors thank the South Africa Department of Science and Technology and the South African National Research Foundation for supporting the specimen repository; the CAPRISA 004 study team, including S. S. Abdool Karim, Q. Abdool Karim, Nonhlanhla Yende, L. Mansoor, J. A. Passmore, J. Frohlich, A. Grobler, A. Kharsany, K. Mlisana, C. Baxter, T. Gengiah, N. Samsunder, and S. Sibeko; the study clinicians, counselors, pharmacists, statisticians, and fieldwork, data quality, laboratory and administrative staff; and the women who participated in the CAPRISA 004 trial, for their contributions.</p>
              <p><bold><italic toggle="yes">Disclaimer.</italic></bold> The funding agencies did not have any role in the study design, the collection, analysis, and interpretation of data, or the writing of the manuscript or its submission for publication.</p>
              <p><bold><italic toggle="yes">Financial support</italic>.</bold> Funding for this research was provided by the Canadian Institutes of Health Research (grant numbers HB3-164066 to A. D. B. and TMI 138658 to A. D. B. and L. R. M.) and the National Institutes of Health (grant number 1R01AI128782 to A. D. B.). Y. W. is a recipient of the Dean’s Summer Research Award from the Case Western Reserve University School of Medicine. The CAPRISA 004 tenofovir gel trial was funded principally by the US Agency for International Development, grants through FHI360, and CONRAD for product manufacturing, with support from the South African Department of Science and Technology. M. P. also reports support for this work from the Public Health Agency of Canada and the University of Manitoba.</p>
            </sec>
            <ref-list id="ref1">
              <title>References</title>
              <ref id="ciac938-B1">
                <label>1</label>
                <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Glynn</surname><given-names>JR</given-names></string-name>, <string-name><surname>Caraël</surname><given-names>M</given-names></string-name>, <string-name><surname>Auvert</surname><given-names>B</given-names></string-name>, <etal>et al</etal></person-group><article-title>Why do young women have a much higher prevalence of HIV than young men? A study in Kisumu, Kenya and Ndola, Zambia</article-title>. <source>AIDS</source><year>2001</year>; <volume>15</volume>:<fpage>S51</fpage>–<lpage>60</lpage>.<pub-id pub-id-type="pmid">11686466</pub-id></mixed-citation>
              </ref>
              <ref id="ciac938-B2">
                <label>2</label>
                <mixed-citation publication-type="other"><person-group person-group-type="author"><collab>Joint United Nations Programme on HIV/AIDS (UNAIDS)</collab></person-group>. <comment>2021 UNAIDS global AIDS update—confronting inequalities—lessons for pandemic responses from 40 years of AIDS.</comment> Geneva, Switzerland: UNAIDS; <year>2021</year>.</mixed-citation>
              </ref>
              <ref id="ciac938-B3">
                <label>3</label>
                <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Birdthistle</surname><given-names>I</given-names></string-name>, <string-name><surname>Tanton</surname><given-names>C</given-names></string-name>, <string-name><surname>Tomita</surname><given-names>A</given-names></string-name>, <etal>et al</etal></person-group><article-title>Recent levels and trends in HIV incidence rates among adolescent girls and young women in ten high-prevalence African countries: a systematic review and meta-analysis</article-title>. <source>Lancet Glob Health</source><year>2019</year>; <volume>7</volume>:<fpage>e1521</fpage>–<lpage>40</lpage>.<pub-id pub-id-type="pmid">31607465</pub-id></mixed-citation>
              </ref>
              <ref id="ciac938-B4">
                <label>4</label>
                <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Birdthistle</surname><given-names>I</given-names></string-name>, <string-name><surname>Kwaro</surname><given-names>D</given-names></string-name>, <string-name><surname>Shahmanesh</surname><given-names>M</given-names></string-name>, <etal>et al</etal></person-group><article-title>Evaluating the impact of DREAMS on HIV incidence among adolescent girls and young women: a population-based cohort study in Kenya and South Africa</article-title>. <source>PLoS Med</source><year>2021</year>; <volume>18</volume>:<fpage>e1003837</fpage>.<pub-id pub-id-type="pmid">34695112</pub-id></mixed-citation>
              </ref>
              <ref id="ciac938-B5">
                <label>5</label>
                <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Abdool Karim</surname><given-names>Q</given-names></string-name>, <string-name><surname>Abdool Karim</surname><given-names>SS</given-names></string-name>, <string-name><surname>Frohlich</surname><given-names>JA</given-names></string-name>, <etal>et al</etal></person-group><article-title>Effectiveness and safety of tenofovir gel, an antiretroviral microbicide, for the prevention of HIV infection in women</article-title>. <source>Science</source><year>2010</year>; <volume>329</volume>:<fpage>1168</fpage>–<lpage>74</lpage>.<pub-id pub-id-type="pmid">20643915</pub-id></mixed-citation>
              </ref>
              <ref id="ciac938-B6">
                <label>6</label>
                <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Baeten</surname><given-names>JM</given-names></string-name>, <string-name><surname>Palanee-Phillips</surname><given-names>T</given-names></string-name>, <string-name><surname>Brown</surname><given-names>ER</given-names></string-name>, <etal>et al</etal></person-group><article-title>Use of a vaginal ring containing dapivirine for HIV-1 prevention in women</article-title>. <source>N Engl J Med</source><year>2016</year>; <volume>375</volume>:<fpage>2121</fpage>–<lpage>32</lpage>.<pub-id pub-id-type="pmid">26900902</pub-id></mixed-citation>
              </ref>
              <ref id="ciac938-B7">
                <label>7</label>
                <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Nel</surname><given-names>A</given-names></string-name>, <string-name><surname>van Niekerk</surname><given-names>N</given-names></string-name>, <string-name><surname>Kapiga</surname><given-names>S</given-names></string-name>, <etal>et al</etal></person-group><article-title>Safety and efficacy of a dapivirine vaginal ring for HIV prevention in women</article-title>. <source>N Engl J Med</source><year>2016</year>; <volume>375</volume>:<fpage>2133</fpage>–<lpage>43</lpage>.<pub-id pub-id-type="pmid">27959766</pub-id></mixed-citation>
              </ref>
              <ref id="ciac938-B8">
                <label>8</label>
                <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Van Damme</surname><given-names>L</given-names></string-name>, <string-name><surname>Corneli</surname><given-names>A</given-names></string-name>, <string-name><surname>Ahmed</surname><given-names>K</given-names></string-name>, <etal>et al</etal></person-group><article-title>Preexposure prophylaxis for HIV infection among African women</article-title>. <source>N Engl J Med</source><year>2012</year>; <volume>367</volume>:<fpage>411</fpage>–<lpage>22</lpage>.<pub-id pub-id-type="pmid">22784040</pub-id></mixed-citation>
              </ref>
              <ref id="ciac938-B9">
                <label>9</label>
                <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Thigpen</surname><given-names>MC</given-names></string-name>, <string-name><surname>Kebaabetswe</surname><given-names>PM</given-names></string-name>, <string-name><surname>Paxton</surname><given-names>LA</given-names></string-name>, <etal>et al</etal></person-group><article-title>Antiretroviral preexposure prophylaxis for heterosexual HIV transmission in Botswana</article-title>. <source>N Engl J Med</source><year>2012</year>; <volume>367</volume>:<fpage>423</fpage>–<lpage>34</lpage>.<pub-id pub-id-type="pmid">22784038</pub-id></mixed-citation>
              </ref>
              <ref id="ciac938-B10">
                <label>10</label>
                <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Baeten</surname><given-names>JM</given-names></string-name>, <string-name><surname>Donnell</surname><given-names>D</given-names></string-name>, <string-name><surname>Ndase</surname><given-names>P</given-names></string-name>, <etal>et al</etal></person-group><article-title>Antiretroviral prophylaxis for HIV prevention in heterosexual men and women</article-title>. <source>N Engl J Med</source><year>2012</year>; <volume>367</volume>:<fpage>399</fpage>–<lpage>410</lpage>.<pub-id pub-id-type="pmid">22784037</pub-id></mixed-citation>
              </ref>
              <ref id="ciac938-B11">
                <label>11</label>
                <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Marrazzo</surname><given-names>JM</given-names></string-name>, <string-name><surname>Ramjee</surname><given-names>G</given-names></string-name>, <string-name><surname>Richardson</surname><given-names>BA</given-names></string-name>, <etal>et al</etal></person-group><article-title>Tenofovir-based preexposure prophylaxis for HIV infection among African women</article-title>. <source>N Engl J Med</source><year>2015</year>; <volume>372</volume>:<fpage>509</fpage>–<lpage>18</lpage>.<pub-id pub-id-type="pmid">25651245</pub-id></mixed-citation>
              </ref>
              <ref id="ciac938-B12">
                <label>12</label>
                <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Delany-Moretlwe</surname><given-names>S</given-names></string-name>, <string-name><surname>Hughes</surname><given-names>JP</given-names></string-name>, <string-name><surname>Bock</surname><given-names>P</given-names></string-name>, <etal>et al</etal></person-group><article-title>Cabotegravir for the prevention of HIV-1 in women: results from HPTN 084, a phase 3, randomised clinical trial</article-title>. <source>Lancet</source><year>2022</year>; <volume>399</volume>:<fpage>1779</fpage>–<lpage>89</lpage>.<pub-id pub-id-type="pmid">35378077</pub-id></mixed-citation>
              </ref>
              <ref id="ciac938-B13">
                <label>13</label>
                <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Yi</surname><given-names>TJ</given-names></string-name>, <string-name><surname>Shannon</surname><given-names>B</given-names></string-name>, <string-name><surname>Prodger</surname><given-names>J</given-names></string-name>, <string-name><surname>McKinnon</surname><given-names>L</given-names></string-name>, <string-name><surname>Kaul</surname><given-names>R</given-names></string-name></person-group>. <article-title>Genital immunology and HIV susceptibility in young women</article-title>. <source>Am J Reprod Immunol</source><year>2013</year>; <volume>69</volume>:<fpage>74</fpage>–<lpage>9</lpage>.<pub-id pub-id-type="pmid">23157424</pub-id></mixed-citation>
              </ref>
              <ref id="ciac938-B14">
                <label>14</label>
                <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Hwang</surname><given-names>LY</given-names></string-name>, <string-name><surname>Scott</surname><given-names>ME</given-names></string-name>, <string-name><surname>Ma</surname><given-names>Y</given-names></string-name>, <string-name><surname>Moscicki</surname><given-names>AB</given-names></string-name></person-group>. <article-title>Higher levels of cervicovaginal inflammatory and regulatory cytokines and chemokines in healthy young women with immature cervical epithelium</article-title>. <source>J Reprod Immunol</source><year>2011</year>; <volume>88</volume>:<fpage>66</fpage>–<lpage>71</lpage>.<pub-id pub-id-type="pmid">21051089</pub-id></mixed-citation>
              </ref>
              <ref id="ciac938-B15">
                <label>15</label>
                <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Madan</surname><given-names>RP</given-names></string-name>, <string-name><surname>Carpenter</surname><given-names>C</given-names></string-name>, <string-name><surname>Fiedler</surname><given-names>T</given-names></string-name>, <etal>et al</etal></person-group><article-title>Altered biomarkers of mucosal immunity and reduced vaginal <italic toggle="yes">Lactobacillus</italic> concentrations in sexually active female adolescents</article-title>. <source>PLoS One</source><year>2012</year>; <volume>7</volume>:<fpage>e40415</fpage>.<pub-id pub-id-type="pmid">22808157</pub-id></mixed-citation>
              </ref>
              <ref id="ciac938-B16">
                <label>16</label>
                <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Abbai</surname><given-names>NS</given-names></string-name>, <string-name><surname>Nyirenda</surname><given-names>M</given-names></string-name>, <string-name><surname>Naidoo</surname><given-names>S</given-names></string-name>, <string-name><surname>Ramjee</surname><given-names>G</given-names></string-name></person-group>. <article-title>Prevalent herpes simplex virus-2 increases the risk of incident bacterial vaginosis in women from South Africa</article-title>. <source>AIDS Behav</source><year>2018</year>; <volume>22</volume>:<fpage>2172</fpage>–<lpage>80</lpage>.<pub-id pub-id-type="pmid">28956191</pub-id></mixed-citation>
              </ref>
              <ref id="ciac938-B17">
                <label>17</label>
                <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Ravel</surname><given-names>J</given-names></string-name>, <string-name><surname>Gajer</surname><given-names>P</given-names></string-name>, <string-name><surname>Abdo</surname><given-names>Z</given-names></string-name>, <etal>et al</etal></person-group><article-title>Vaginal microbiome of reproductive-age women</article-title>. <source>Proc Natl Acad Sci U S A</source><year>2011</year>; <volume>108</volume>:<fpage>4680</fpage>–<lpage>7</lpage>.<pub-id pub-id-type="pmid">20534435</pub-id></mixed-citation>
              </ref>
              <ref id="ciac938-B18">
                <label>18</label>
                <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Zevin</surname><given-names>AS</given-names></string-name>, <string-name><surname>Xie</surname><given-names>IY</given-names></string-name>, <string-name><surname>Birse</surname><given-names>K</given-names></string-name>, <etal>et al</etal></person-group><article-title>Microbiome composition and function drives wound-healing impairment in the female genital tract</article-title>. <source>PLoS Pathog</source><year>2016</year>; <volume>12</volume>:<fpage>e1005889</fpage>.<pub-id pub-id-type="pmid">27656899</pub-id></mixed-citation>
              </ref>
              <ref id="ciac938-B19">
                <label>19</label>
                <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Srinivasan</surname><given-names>S</given-names></string-name>, <string-name><surname>Morgan</surname><given-names>MT</given-names></string-name>, <string-name><surname>Fiedler</surname><given-names>TL</given-names></string-name>, <etal>et al</etal></person-group><article-title>Metabolic signatures of bacterial vaginosis</article-title>. <source>MBio</source><year>2015</year>; <volume>6:</volume><fpage>e00204</fpage>–<lpage>15</lpage>.<pub-id pub-id-type="pmid">25873373</pub-id></mixed-citation>
              </ref>
              <ref id="ciac938-B20">
                <label>20</label>
                <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Mirmonsef</surname><given-names>P</given-names></string-name>, <string-name><surname>Krass</surname><given-names>L</given-names></string-name>, <string-name><surname>Landay</surname><given-names>A</given-names></string-name>, <string-name><surname>Spear</surname><given-names>GT</given-names></string-name></person-group>. <article-title>The role of bacterial vaginosis and trichomonas in HIV transmission across the female genital tract</article-title>. <source>Curr HIV Res</source><year>2012</year>; <volume>10</volume>:<fpage>202</fpage>–<lpage>10</lpage>.<pub-id pub-id-type="pmid">22384839</pub-id></mixed-citation>
              </ref>
              <ref id="ciac938-B21">
                <label>21</label>
                <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Anahtar</surname><given-names>MN</given-names></string-name>, <string-name><surname>Byrne</surname><given-names>EH</given-names></string-name>, <string-name><surname>Doherty</surname><given-names>KE</given-names></string-name>, <etal>et al</etal></person-group><article-title>Cervicovaginal bacteria are a major modulator of host inflammatory responses in the female genital tract</article-title>. <source>Immunity</source><year>2015</year>; <volume>42</volume>:<fpage>965</fpage>–<lpage>76</lpage>.<pub-id pub-id-type="pmid">25992865</pub-id></mixed-citation>
              </ref>
              <ref id="ciac938-B22">
                <label>22</label>
                <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Borgdorff</surname><given-names>H</given-names></string-name>, <string-name><surname>Tsivtsivadze</surname><given-names>E</given-names></string-name>, <string-name><surname>Verhelst</surname><given-names>R</given-names></string-name>, <etal>et al</etal></person-group><article-title><italic toggle="yes">Lactobacillus</italic>-dominated cervicovaginal microbiota associated with reduced HIV/STI prevalence and genital HIV viral load in African women</article-title>. <source>ISME J</source><year>2014</year>; <volume>8</volume>:<fpage>1781</fpage>–<lpage>93</lpage>.<pub-id pub-id-type="pmid">24599071</pub-id></mixed-citation>
              </ref>
              <ref id="ciac938-B23">
                <label>23</label>
                <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Gosmann</surname><given-names>C</given-names></string-name>, <string-name><surname>Anahtar</surname><given-names>MN</given-names></string-name>, <string-name><surname>Handley</surname><given-names>SA</given-names></string-name>, <etal>et al</etal></person-group><article-title><italic toggle="yes">Lactobacillus</italic>-deficient cervicovaginal bacterial communities are associated with increased HIV acquisition in young South African women</article-title>. <source>Immunity</source><year>2017</year>; <volume>46</volume>:<fpage>29</fpage>–<lpage>37</lpage>.<pub-id pub-id-type="pmid">28087240</pub-id></mixed-citation>
              </ref>
              <ref id="ciac938-B24">
                <label>24</label>
                <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Klatt</surname><given-names>NR</given-names></string-name>, <string-name><surname>Cheu</surname><given-names>R</given-names></string-name>, <string-name><surname>Birse</surname><given-names>K</given-names></string-name>, <etal>et al</etal></person-group><article-title>Vaginal bacteria modify HIV tenofovir microbicide efficacy in African women</article-title>. <source>Science</source><year>2017</year>; <volume>356</volume>:<fpage>938</fpage>–<lpage>45</lpage>.<pub-id pub-id-type="pmid">28572388</pub-id></mixed-citation>
              </ref>
              <ref id="ciac938-B25">
                <label>25</label>
                <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Karim</surname><given-names>SSA</given-names></string-name>, <string-name><surname>Baxter</surname><given-names>C</given-names></string-name></person-group>. <article-title>HIV incidence rates in adolescent girls and young women in sub-Saharan Africa</article-title>. <source>Lancet Glob Health</source><year>2019</year>; <volume>7</volume>:<fpage>e1470</fpage>–<lpage>1</lpage>.<pub-id pub-id-type="pmid">31607449</pub-id></mixed-citation>
              </ref>
              <ref id="ciac938-B26">
                <label>26</label>
                <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Noël-Romas</surname><given-names>L</given-names></string-name>, <string-name><surname>Perner</surname><given-names>M</given-names></string-name>, <string-name><surname>Molatlhegi</surname><given-names>R</given-names></string-name>, <etal>et al</etal></person-group><article-title>Vaginal microbiome-hormonal contraceptive interactions associate with the mucosal proteome and HIV acquisition</article-title>. <source>PLoS Pathog</source><year>2020</year>; <volume>16</volume>:<fpage>e1009097</fpage>.<pub-id pub-id-type="pmid">33362285</pub-id></mixed-citation>
              </ref>
              <ref id="ciac938-B27">
                <label>27</label>
                <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>McClelland</surname><given-names>RS</given-names></string-name>, <string-name><surname>Lingappa</surname><given-names>JR</given-names></string-name>, <string-name><surname>Srinivasan</surname><given-names>S</given-names></string-name>, <etal>et al</etal></person-group><article-title>Evaluation of the association between the concentrations of key vaginal bacteria and the increased risk of HIV acquisition in African women from five cohorts: a nested case-control study</article-title>. <source>Lancet Infect Dis</source><year>2018</year>; <volume>18</volume>:<fpage>554</fpage>–<lpage>64.</lpage><pub-id pub-id-type="pmid">29396006</pub-id></mixed-citation>
              </ref>
              <ref id="ciac938-B28">
                <label>28</label>
                <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Hickey</surname><given-names>RJ</given-names></string-name>, <string-name><surname>Zhou</surname><given-names>X</given-names></string-name>, <string-name><surname>Settles</surname><given-names>ML</given-names></string-name>, <etal>et al</etal></person-group><article-title>Vaginal microbiota of adolescent girls prior to the onset of menarche resemble those of reproductive-age women</article-title>. <source>mBio</source><year>2015</year>; <volume>6</volume>:<fpage>e00097-15</fpage>.<pub-id pub-id-type="pmid">25805726</pub-id></mixed-citation>
              </ref>
              <ref id="ciac938-B29">
                <label>29</label>
                <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>France</surname><given-names>MT</given-names></string-name>, <string-name><surname>Ma</surname><given-names>B</given-names></string-name>, <string-name><surname>Gajer</surname><given-names>P</given-names></string-name>, <etal>et al</etal></person-group><article-title>VALENCIA: a nearest centroid classification method for vaginal microbial communities based on composition</article-title>. <source>Microbiome</source><year>2020</year>; <volume>8</volume>:<fpage>166</fpage>.<pub-id pub-id-type="pmid">33228810</pub-id></mixed-citation>
              </ref>
              <ref id="ciac938-B30">
                <label>30</label>
                <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Hummelen</surname><given-names>R</given-names></string-name>, <string-name><surname>Fernandes</surname><given-names>AD</given-names></string-name>, <string-name><surname>Macklaim</surname><given-names>JM</given-names></string-name>, <etal>et al</etal></person-group><article-title>Deep sequencing of the vaginal microbiota of women with HIV</article-title>. <source>PLoS One</source><year>2010</year>; <volume>5</volume>:<fpage>e12078</fpage>.<pub-id pub-id-type="pmid">20711427</pub-id></mixed-citation>
              </ref>
              <ref id="ciac938-B31">
                <label>31</label>
                <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Schellenberg</surname><given-names>JJ</given-names></string-name>, <string-name><surname>Card</surname><given-names>CM</given-names></string-name>, <string-name><surname>Ball</surname><given-names>TB</given-names></string-name>, <etal>et al</etal></person-group><article-title>Bacterial vaginosis, HIV serostatus and T-cell subset distribution in a cohort of East African commercial sex workers: retrospective analysis</article-title>. <source>AIDS</source><year>2012</year>; <volume>26</volume>:<fpage>387</fpage>–<lpage>93</lpage>.<pub-id pub-id-type="pmid">22095193</pub-id></mixed-citation>
              </ref>
              <ref id="ciac938-B32">
                <label>32</label>
                <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Alisoltani</surname><given-names>A</given-names></string-name>, <string-name><surname>Manhanzva</surname><given-names>MT</given-names></string-name>, <string-name><surname>Potgieter</surname><given-names>M</given-names></string-name>, <etal>et al</etal></person-group><article-title>Microbial function and genital inflammation in young South African women at high risk of HIV infection</article-title>. <source>Microbiome</source><year>2020</year>; <volume>8:</volume><fpage>165.</fpage><pub-id pub-id-type="pmid">33220709</pub-id></mixed-citation>
              </ref>
              <ref id="ciac938-B33">
                <label>33</label>
                <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Burgener</surname><given-names>A</given-names></string-name>, <string-name><surname>McGowan</surname><given-names>I</given-names></string-name>, <string-name><surname>Klatt</surname><given-names>NR</given-names></string-name></person-group>. <article-title>HIV and mucosal barrier interactions: consequences for transmission and pathogenesis</article-title>. <source>Curr Opin Immunol</source><year>2015</year>; <volume>36</volume>:<fpage>22</fpage>–<lpage>30</lpage>.<pub-id pub-id-type="pmid">26151777</pub-id></mixed-citation>
              </ref>
              <ref id="ciac938-B34">
                <label>34</label>
                <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Haase</surname><given-names>AT</given-names></string-name></person-group>. <article-title>Early events in sexual transmission of HIV and SIV and opportunities for interventions</article-title>. <source>Ann Rev Med</source><year>2011</year>; <volume>62</volume>:<fpage>127</fpage>–<lpage>39</lpage>.<pub-id pub-id-type="pmid">21054171</pub-id></mixed-citation>
              </ref>
              <ref id="ciac938-B35">
                <label>35</label>
                <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Douek</surname><given-names>DC</given-names></string-name>, <string-name><surname>Brenchley</surname><given-names>JM</given-names></string-name>, <string-name><surname>Betts</surname><given-names>MR</given-names></string-name>, <etal>et al</etal></person-group><article-title>HIV preferentially infects HIV-specific CD4+ T cells</article-title>. <source>Nature</source><year>2002</year>; <volume>417</volume>:<fpage>95</fpage>–<lpage>8</lpage>.<pub-id pub-id-type="pmid">11986671</pub-id></mixed-citation>
              </ref>
              <ref id="ciac938-B36">
                <label>36</label>
                <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Carnathan</surname><given-names>DG</given-names></string-name>, <string-name><surname>Wetzel</surname><given-names>KS</given-names></string-name>, <string-name><surname>Yu</surname><given-names>J</given-names></string-name>, <etal>et al</etal></person-group><article-title>Activated CD4<sup>+</sup>CCR5<sup>+</sup> T cells in the rectum predict increased SIV acquisition in SIVGag/Tat-vaccinated rhesus macaques</article-title>. <source>Proc Natl Acad Sci U S A</source><year>2015</year>; <volume>112</volume>:<fpage>518</fpage>–<lpage>23</lpage>.<pub-id pub-id-type="pmid">25550504</pub-id></mixed-citation>
              </ref>
              <ref id="ciac938-B37">
                <label>37</label>
                <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Borgdorff</surname><given-names>H</given-names></string-name>, <string-name><surname>Gautam</surname><given-names>R</given-names></string-name>, <string-name><surname>Armstrong</surname><given-names>SD</given-names></string-name>, <etal>et al</etal></person-group><article-title>Cervicovaginal microbiome dysbiosis is associated with proteome changes related to alterations of the cervicovaginal mucosal barrier</article-title>. <source>Mucosal Immunol</source><year>2016</year>; <volume>9</volume>:<fpage>621</fpage>–<lpage>33</lpage>.<pub-id pub-id-type="pmid">26349657</pub-id></mixed-citation>
              </ref>
              <ref id="ciac938-B38">
                <label>38</label>
                <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Carias</surname><given-names>AM</given-names></string-name>, <string-name><surname>Allen</surname><given-names>SA</given-names></string-name>, <string-name><surname>Fought</surname><given-names>AJ</given-names></string-name>, <etal>et al</etal></person-group><article-title>Increases in endogenous or exogenous progestins promote virus-target cell interactions within the non-human primate female reproductive tract</article-title>. <source>PLoS Pathog</source><year>2016</year>; <volume>12</volume>:<fpage>e1005885</fpage>.<pub-id pub-id-type="pmid">27658293</pub-id></mixed-citation>
              </ref>
              <ref id="ciac938-B39">
                <label>39</label>
                <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Arnold</surname><given-names>KB</given-names></string-name>, <string-name><surname>Burgener</surname><given-names>A</given-names></string-name>, <string-name><surname>Birse</surname><given-names>K</given-names></string-name>, <etal>et al</etal></person-group><article-title>Increased levels of inflammatory cytokines in the female reproductive tract are associated with altered expression of proteases, mucosal barrier proteins, and an influx of HIV-susceptible target cells</article-title>. <source>Mucosal Immunol</source><year>2016</year>; <volume>9</volume>:<fpage>194</fpage>–<lpage>205</lpage>.<pub-id pub-id-type="pmid">26104913</pub-id></mixed-citation>
              </ref>
              <ref id="ciac938-B40">
                <label>40</label>
                <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Liebenberg</surname><given-names>LJP</given-names></string-name>, <string-name><surname>McKinnon</surname><given-names>LR</given-names></string-name>, <string-name><surname>Yende-Zuma</surname><given-names>N</given-names></string-name>, <etal>et al</etal></person-group><article-title>HPV infection and the genital cytokine milieu in women at high risk of HIV acquisition</article-title>. <source>Nat Commun</source><year>2019</year>; <volume>10</volume>:<fpage>5227</fpage>.<pub-id pub-id-type="pmid">31745084</pub-id></mixed-citation>
              </ref>
              <ref id="ciac938-B41">
                <label>41</label>
                <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Delgado-Diaz</surname><given-names>DJ</given-names></string-name>, <string-name><surname>Jesaveluk</surname><given-names>B</given-names></string-name>, <string-name><surname>Hayward</surname><given-names>JA</given-names></string-name>, <etal>et al</etal></person-group><article-title>Lactic acid from vaginal microbiota enhances cervicovaginal epithelial barrier integrity by promoting tight junction protein expression</article-title>. <source>Microbiome</source><year>2022</year>; <volume>10</volume>:<fpage>141</fpage>.<pub-id pub-id-type="pmid">36045402</pub-id></mixed-citation>
              </ref>
              <ref id="ciac938-B42">
                <label>42</label>
                <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Zhang</surname><given-names>Y</given-names></string-name>, <string-name><surname>Bhosle</surname><given-names>A</given-names></string-name>, <string-name><surname>Bae</surname><given-names>S</given-names></string-name>, <etal>et al</etal></person-group><article-title>Discovery of bioactive microbial gene products in inflammatory bowel disease</article-title>. <source>Nature</source><year>2022</year>; <volume>606</volume>:<fpage>754</fpage>–<lpage>60</lpage>.<pub-id pub-id-type="pmid">35614211</pub-id></mixed-citation>
              </ref>
              <ref id="ciac938-B43">
                <label>43</label>
                <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Cohen</surname><given-names>CR</given-names></string-name>, <string-name><surname>Wierzbicki</surname><given-names>MR</given-names></string-name>, <string-name><surname>French</surname><given-names>AL</given-names></string-name>, <etal>et al</etal></person-group><article-title>Randomized trial of lactin-V to prevent recurrence of bacterial vaginosis</article-title>. <source>N Engl J Med</source><year>2020</year>; <volume>382</volume>:<fpage>1906</fpage>–<lpage>15</lpage>.<pub-id pub-id-type="pmid">32402161</pub-id></mixed-citation>
              </ref>
              <ref id="ciac938-B44">
                <label>44</label>
                <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Lev-Sagie</surname><given-names>A</given-names></string-name>, <string-name><surname>Goldman-Wohl</surname><given-names>D</given-names></string-name>, <string-name><surname>Cohen</surname><given-names>Y</given-names></string-name>, <etal>et al</etal></person-group><article-title>Vaginal microbiome transplantation in women with intractable bacterial vaginosis</article-title>. <source>Nat Med</source><year>2019</year>; <volume>25</volume>:<fpage>1500</fpage>–<lpage>4</lpage>.<pub-id pub-id-type="pmid">31591599</pub-id></mixed-citation>
              </ref>
              <ref id="ciac938-B45">
                <label>45</label>
                <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Happel</surname><given-names>AU</given-names></string-name>, <string-name><surname>Kullin</surname><given-names>B</given-names></string-name>, <string-name><surname>Gamieldien</surname><given-names>H</given-names></string-name>, <etal>et al</etal></person-group><article-title>Exploring potential of vaginal <italic toggle="yes">Lactobacillus</italic> isolates from South African women for enhancing treatment for bacterial vaginosis</article-title>. <source>PLoS Pathog</source><year>2020</year>; <volume>16</volume>:<fpage>e1008559</fpage>.<pub-id pub-id-type="pmid">32497109</pub-id></mixed-citation>
              </ref>
            </ref-list>
          </back>
        </article>
      </metadata>
    </record>
  </GetRecord>
</OAI-PMH>
